Myriad Genetics, Inc
(NASDAQ:MYGN)

Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company offers myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test...

Website: http://www.myriad.com

Founded: 1991

Full Time Employees: 2,700

Sector: Healthcare

Industry: Diagnostics & Research

Pharmaceuticals Genetics

Share this website to your friends

• Market Cap:

• Exchange:

• Shs Outstanding:

• Employees:

• Beta:

• Return on Equity (ROE) ttm:

• Return on Assets (ROA) ttm:

• EPS ttm:

• Book value per Share:

• Cash per Share:

• Current ast per Share:

• P/E ttm:

• P/E forward:

• P/E ttm high:

• P/E ttm low:

• P/S ttm:

• P/B ttm:

• P/FCF ttm:

• PEG ratio:

• Cash Ratio ttm:

• Quick Ratio ttm:

• Current Ratio ttm:

• Gross Mgn ttm:

• EBITDA Mgn ttm:

• Operating Mgn ttm:

• Net Income Mgn ttm:

• Trailing Div yield:

• Forward Div yield:

• Payout Ratio ttm:

• Ex-Dividend date:

• Target Price High:

• Target Price Low:

• Target Price Mean:

• Number of Analysts:

• Debt Ratio ttm:

• Debt to Equity ttm:

• Total Net Debt:

At a glance:

Bull Thesis:

Bear Thesis:

Main Competitors:

Moat:

Income Statements:

Quarterly

Annual

Unit: USD	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30	2004-06-30	2004-03-31	2003-12-31	2003-09-30	2003-06-30	2003-03-31	2002-12-31	2002-09-30	2002-06-30	2002-03-31	2001-12-31

revenue	200,400,000	209,800,000	205,700,000	213,100,000	195,900,000																																																						73,668,000	102,374,000	100,440,000	91,858,000
yoy	2.30%
qoq	-4.48%	1.99%	-3.47%	8.78%																																																							-28.04%	1.93%	9.34%
cost of revenue	62,800,000	63,000,000	61,900,000	61,300,000	61,700,000																																																						8,547,750	11,133,000	12,046,000	11,011,000
gross profit	137,600,000	146,800,000	143,800,000	151,800,000	134,200,000
yoy	2.53%
qoq	-6.27%	2.09%	-5.27%	13.11%
gross margin %	68.66%	69.97%	69.91%	71.23%	68.50%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	0%	0%	0%	0%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%
costs and expenses:
research and development expense	27,100,000	25,500,000	28,200,000	25,600,000	27,500,000	32,200,000	28,500,000	27,100,000	24,900,000	21,000,000	24,000,000	21,200,000	22,500,000	23,400,000	20,500,000	20,300,000	21,200,000	20,500,000	18,800,000	19,500,000	23,100,000	17,600,000	17,400,000	19,700,000	18,800,000	21,300,000	20,900,000	21,500,000	22,400,000	21,100,000	17,700,000	18,500,000	16,800,000	17,800,000	18,800,000	17,600,000	18,600,000	19,400,000	19,500,000	17,200,000	16,700,000	17,200,000	18,712,000	16,673,000	17,504,000	22,612,000	20,187,000	13,397,000	17,090,000	16,803,000	14,581,000	13,618,000	14,107,000	11,400,000	12,143,000	11,753,000	10,243,000	8,505,000	9,231,000	6,667,000	6,092,000	5,762,000	5,253,000	5,885,000	5,059,000	5,676,000	-37,036,000	17,850,000	19,952,000	17,149,000	55,225,000	31,161,000	27,306,000	26,025,000	26,175,000	23,418,000	24,764,000	26,352,000	24,294,000	21,967,000	19,030,000	18,466,000			14,546,000		9,673,250	12,390,000	11,558,000	12,974,000	13,372,000	11,053,000	12,218,000
sales and marketing expense	73,600,000	68,700,000	71,000,000	71,900,000	69,200,000
general and administrative expense	62,200,000	55,600,000	67,900,000	66,800,000	66,500,000
goodwill and long-lived asset impairment charges	5,400,000	2,700,000		316,700,000		43,000,000	2,200,000	11,600,000						6,200,000			10,700,000			1,800,000
total operating expenses	168,300,000	152,500,000	167,100,000	481,000,000	163,200,000
operating income	-30,700,000	-5,700,000	-23,300,000	-329,200,000	-29,000,000	-39,000,000	-20,000,000	-36,500,000	-27,900,000	-31,400,000	-60,100,000	-113,700,000	-52,200,000	-52,200,000	-45,000,000	-17,800,000	-25,600,000	-43,100,000	-79,900,000	-20,800,000	-46,700,000	-39,600,000	-68,300,000	-133,700,000	-8,800,000	-20,900,000	-5,600,000	5,900,000	6,100,000	1,200,000	9,700,000	17,000,000	4,400,000	87,400,000	17,000,000	12,900,000	13,200,000	6,200,000	35,600,000	42,600,000	45,200,000	43,300,000	36,198,000	35,740,000	36,342,000	25,920,000	53,254,000	55,287,000	82,999,000	82,904,000	65,916,000	57,918,000	55,586,000	48,582,000	47,286,000	46,096,000	45,465,000	41,472,000	41,777,000	41,824,000	38,586,000	35,591,000	37,615,000	33,225,000	34,522,000	29,712,000	73,073,000	22,311,000	17,766,000	13,312,000	66,214,000	-7,816,000	-8,736,000	-11,582,000	-12,266,000	-9,092,000	-11,369,000	-15,000,000	-13,981,000	-11,954,000	-9,600,000	-10,053,000					-7,928,250	-11,164,000	-10,381,000	-10,168,000
yoy	5.86%	-85.38%	16.50%	801.92%	3.94%	24.20%	-66.72%	-67.90%	-46.55%	-39.85%	33.56%	538.76%	103.91%	21.11%	-43.68%	-14.42%	-45.18%	8.84%	16.98%	-84.44%	430.68%	89.47%	1119.64%	-2366.10%	-244.26%	-1841.67%	-157.73%	-65.29%	38.64%	-98.63%	-42.94%	31.78%	-66.67%	1309.68%	-52.25%	-69.72%	-70.80%	-85.68%	-1.65%	19.19%	24.37%	67.05%	-32.03%	-35.36%	-56.21%	-68.73%	-19.21%	-4.54%	49.32%	70.65%	39.40%	25.65%	22.26%	17.14%	13.19%	10.21%	17.83%	16.52%	11.06%	25.88%	11.77%	19.79%	-48.52%	48.92%	94.31%	123.20%	10.36%	-385.45%	-303.37%	-214.94%	-639.82%	-14.03%	-23.16%	-22.79%	-12.27%	-23.94%	18.43%	49.21%
qoq	438.60%	-75.54%	-92.92%	1035.17%	-25.64%	95.00%	-45.21%	30.82%	-11.15%	-47.75%	-47.14%	117.82%	0.00%	16.00%	152.81%	-30.47%	-40.60%	-46.06%	284.13%	-55.46%	17.93%	-42.02%	-48.92%	1419.32%	-57.89%	273.21%	-194.92%	-3.28%	408.33%	-87.63%	-42.94%	286.36%	-94.97%	414.12%	31.78%	-2.27%	112.90%	-82.58%	-16.43%	-5.75%	4.39%	19.62%	1.28%	-1.66%	40.21%	-51.33%	-3.68%	-33.39%	0.11%	25.77%	13.81%	4.20%	14.42%	2.74%	2.58%	1.39%	9.63%	-0.73%	-0.11%	8.39%	8.42%	-5.38%	13.21%	-3.76%	16.19%	-59.34%	227.52%	25.58%	33.46%	-79.90%	-947.16%	-10.53%	-24.57%	-5.58%	34.91%	-20.03%	-24.21%	7.29%	16.96%	24.52%	-4.51%						-28.98%	7.54%	2.09%
operating margin %	-15.32%	-2.72%	-11.33%	-154.48%	-14.80%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	56.71%	40.85%	38.42%	38.75%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	NaN%	NaN%	NaN%	NaN%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%
other income:
interest income	700,000	800,000	500,000	200,000	300,000	300,000	400,000	400,000	600,000	700,000	600,000	500,000	700,000	1,000,000	1,100,000	400,000	100,000	100,000	200,000	200,000	200,000	400,000	500,000	800,000	800,000	900,000	900,000	700,000	900,000	700,000	600,000	500,000	400,000	400,000	300,000	300,000	300,000	300,000	400,000	300,000	100,000	100,000	135,000	124,000	85,000	55,000	207,000	2,498,000	1,330,000	1,362,000	1,310,000	1,434,000	1,385,000	1,368,000	1,394,000	1,379,000	1,382,000	473,000	410,000	547,000	548,000	721,000	984,000	1,232,000	1,531,000	1,913,000	2,661,000	2,946,000	3,437,000	3,434,000	2,935,000	3,250,000	3,667,000	3,857,000	3,814,000	3,123,000	2,573,000	2,602,000	2,545,000	2,407,000	1,649,000	811,000			687,000		392,250	473,000	527,000	569,000	632,000	701,000	725,000
interest expense	-4,100,000	-4,400,000	-3,800,000	-1,500,000	-800,000	-700,000	-800,000	-800,000	-500,000	-900,000	-1,000,000	-500,000	-500,000	-900,000	-800,000	-600,000	-900,000	-500,000	-1,100,000	-2,000,000	-3,000,000	-2,900,000	-3,100,000	-2,300,000	-2,500,000	-2,900,000	-3,200,000	-3,200,000	-3,400,000	-2,200,000	-1,000,000	-500,000	-700,000	-900,000	-1,200,000	-1,500,000	-2,600,000
other		400,000	400,000	-100,000	100,000	300,000	-800,000	-300,000	1,900,000	-700,000	-700,000	-2,400,000	-600,000		500,000	100,000			120,600,000	18,800,000	-100,000	-1,600,000	12,400,000	4,100,000	-900,000	600,000	200,000	-100,000		1,100,000	900,000	-500,000	-400,000	-300,000	-100,000	1,500,000	1,200,000	-2,500,000		200,000	-300,000	100,000				-98,000	-908,000	-442,000	-185,000	-439,000	1,000	-111,000	14,000	-128,000	-208,000	6,000	-64,000	-140,000	-80,000	-59,000	-80,000	-134,000	5,000	23,000	286,000	-215,000	-455,000	-33,000		-2,005,000	-3,000,000	-65,000	2,000	-274,000	648,000	32,000		-27,000	12,000	-24,000	-1,000						-3,750	-5,000		-10,000	3,000	1,000
total other expense	-3,400,000									-975,000	-1,100,000	-2,400,000	-400,000									-4,100,000
loss before income tax	-34,100,000	-8,900,000	-26,200,000	-330,600,000	-29,400,000	-39,100,000	-21,200,000	-37,200,000	-25,900,000	-32,300,000	-61,200,000	-116,100,000	-52,600,000			-17,900,000	-26,400,000			-3,800,000	-49,600,000	-43,700,000
income tax benefit				-100,000													-5,900,000				-10,100,000	-28,500,000
net income	-34,100,000	-7,900,000	-27,400,000	-330,500,000	-100,000	-42,500,000	-22,100,000	-36,700,000	-26,000,000	-31,200,000	-61,300,000	-116,100,000	-54,700,000	-42,300,000	-35,100,000	-14,100,000	-20,500,000	-7,600,000	24,600,000	-4,700,000	-39,500,000	-15,200,000	-55,500,000	-115,200,000	-8,300,000	-20,600,000	-4,300,000	6,900,000	2,600,000	-800,000	6,500,000	11,300,000	32,100,000	81,000,000	12,700,000	4,200,000	5,900,000	-1,200,000	35,700,000	32,600,000	30,300,000	26,600,000	18,712,000	21,475,000	24,031,000	15,982,000	33,632,000	36,770,000	50,360,000	55,465,000	44,074,000	37,892,000	35,036,000	30,136,000	29,142,000	29,615,000	28,296,000	25,099,000	26,040,000	27,940,000	24,191,000	22,538,000	53,250,000	33,251,000	35,359,000	30,442,000	23,640,000	25,318,000	21,203,000	14,454,000	65,541,000	-4,631,000	-5,067,000	-7,999,000	-7,804,000	-5,937,000	-8,796,000	-12,425,000	-11,424,000	-9,571,000	-7,952,000	-9,242,000			-10,048,000		-7,539,750	-10,696,000	-9,854,000	-9,609,000	-7,081,000	-5,534,000	-6,894,000
yoy	34000.00%	-81.41%	23.98%	800.54%	-99.62%	36.22%	-63.95%	-68.39%	-52.47%	-26.24%	74.64%	723.40%	166.83%	456.58%	-242.68%	200.00%	-48.10%	-50.00%	-144.32%	-95.92%	375.90%	-26.21%	1190.70%	-1769.57%	-419.23%	2475.00%	-166.15%	-38.94%	-91.90%	-100.99%	-48.82%	169.05%	444.07%	-6850.00%	-64.43%	-87.12%	-80.53%	-104.51%	90.79%	51.80%	26.09%	66.44%	-44.36%	-41.60%	-52.28%	-71.19%	-23.69%	-2.96%	43.74%	84.05%	51.24%	27.95%	23.82%	20.07%	11.91%	5.99%	16.97%	11.36%	-51.10%	-15.97%	-31.58%	-25.96%	125.25%	31.33%	66.76%	110.61%	-63.93%	-646.71%	-518.45%	-280.70%	-939.84%	-22.00%	-42.39%	-35.62%	-31.69%	-37.97%	10.61%	34.44%			-20.86%				1.97%		6.48%	93.28%	42.94%
qoq	331.65%	-71.17%	-91.71%	330400.00%	-99.76%	92.31%	-39.78%	41.15%	-16.67%	-49.10%	-47.20%	112.25%	29.31%	20.51%	148.94%	-31.22%	169.74%	-130.89%	-623.40%	-88.10%	159.87%	-72.61%	-51.82%	1287.95%	-59.71%	379.07%	-162.32%	165.38%	-425.00%	-112.31%	-42.48%	-64.80%	-60.37%	537.80%	202.38%	-28.81%	-591.67%	-103.36%	9.51%	7.59%	13.91%	42.15%	-12.87%	-10.64%	50.36%	-52.48%	-8.53%	-26.99%	-9.20%	25.85%	16.31%	8.15%	16.26%	3.41%	-1.60%	4.66%	12.74%	-3.61%	-6.80%	15.50%	7.33%	-57.68%	60.15%	-5.96%	16.15%	28.77%	-6.63%	19.41%	46.69%	-77.95%	-1515.27%	-8.60%	-36.65%	2.50%	31.45%	-32.50%	-29.21%	8.76%	19.36%	20.36%	-13.96%						-29.51%	8.54%	2.55%	35.70%	27.95%	-19.73%
net income margin %	-17.02%	-3.77%	-13.32%	-155.09%	-0.05%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	Infinity%	Infinity%	-Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	-Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	35.35%	27.29%	24.09%	24.54%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	NaN%	NaN%	-Infinity%	NaN%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	NaN%	NaN%	NaN%	NaN%
net income per share
basic and diluted	-0.36	-0.07	-0.29	-3.57		-0.47	-0.24	-0.41	-0.29	-0.34	-0.75	-1.42	-0.67			-0.18	-0.26			-0.06	-0.52	-0.2
weighted-average shares outstanding:
basic and diluted	93.7	92.6	93.1	92.5	91.4	90.6	90.9	90.6	89.9	82.8	81.9	81.7	81.3	80.6		80.4	80.1			77.2	76	74.7
total other income		-1,175,000	-2,900,000	-1,400,000	-400,000	25,000	-1,200,000	-700,000	2,000,000					-25,000	800,000	-100,000	-800,000	-400,000	119,700,000	17,000,000	-2,900,000																						345,500	-174,000	1,598,000	-43,000	1,031,000	2,056,000	1,145,000	923,000	990,750	1,323,000	1,399,000	1,240,000	1,186,000	1,385,000	1,318,000	333,000	330,000	488,000	468,000	587,000	989,000	1,255,000	1,817,000	1,698,000	2,206,000	2,913,000	3,437,000	1,429,000
income tax expense		-1,000,000	1,200,000		-29,300,000	3,400,000	900,000	-500,000	100,000	-1,100,000	100,000		2,100,000	-4,700,000	-9,100,000	-3,800,000		1,500,000	15,200,000	900,000
testing revenue						156,750,000	213,300,000	211,500,000	202,200,000	196,600,000	191,900,000	183,500,000	181,200,000
cost of testing revenue						48,125,000	63,500,000	64,400,000	64,600,000	61,600,000	57,600,000	57,800,000	59,200,000
selling, general, and administrative expense						106,000,000	139,100,000	144,900,000	140,600,000	144,400,000	136,100,000	140,700,000	151,700,000	146,500,000	130,500,000	127,100,000	110,600,000	77,300,000	180,200,000	134,800,000	145,500,000	124,100,000	107,400,000	132,900,000	135,600,000	135,500,000	149,800,000	140,600,000	135,200,000	129,900,000	121,600,000	115,100,000	115,400,000	115,200,000	122,100,000	122,100,000	120,300,000	111,900,000	91,300,000	90,500,000	90,800,000	86,500,000	96,585,000	91,279,000	92,695,000	85,440,000	84,345,000	87,631,000	77,840,000	77,279,000	71,545,000	64,602,000	59,563,000	56,128,000	56,584,000	54,700,000	50,986,000	46,114,000	43,881,000	42,750,000	43,716,000	39,494,000	39,798,000	40,840,000	42,104,000	38,672,000	33,792,000	36,094,000	35,598,000	33,399,000	36,366,000	30,157,000	30,482,000	26,488,000
legal settlements
total costs and expenses						177,875,000	233,300,000	248,000,000	230,100,000	228,000,000	252,000,000	297,200,000	233,400,000	230,000,000	201,400,000	197,100,000	190,500,000	203,900,000	247,200,000	210,200,000	219,800,000	184,800,000	161,500,000	297,700,000	203,900,000	207,200,000	221,000,000	210,700,000	210,700,000	201,100,000	185,200,000	176,500,000	189,600,000	102,800,000	183,500,000	184,000,000	183,300,000	171,300,000	150,800,000	147,900,000	148,100,000	140,200,000	153,686,000	144,245,000	148,051,000	142,917,000	135,512,000	127,637,000	121,061,000	119,563,000	108,199,000	98,554,000	93,554,000	84,855,000	85,679,000	83,681,000	77,346,000	68,980,000	65,635,000	60,550,000	61,854,000	56,267,000	56,313,000	57,605,000	58,246,000	55,410,000	7,941,000	65,176,000	66,610,000	60,338,000	100,642,000	69,581,000	65,478,000	59,848,000	57,744,000	50,062,000	48,504,000	48,543,000	46,006,000	41,763,000	36,930,000	35,167,000			30,315,000		18,322,250	24,920,000	24,529,000	23,840,000	23,378,000	22,199,000	24,508,000
legal charges pending settlement										27,950,000	34,300,000	77,500,000
revenues:
molecular diagnostic testing														125,150,000	156,400,000	179,300,000	164,900,000	160,800,000	167,300,000	178,700,000	159,600,000	135,700,000	83,300,000	150,500,000	181,100,000	172,000,000	196,900,000	200,500,000	203,000,000	189,000,000	181,700,000	179,700,000	179,200,000	178,800,000	187,900,000	185,200,000	183,900,000	165,100,000	173,700,000	177,400,000	182,600,000	171,900,000	178,866,000	172,978,000	179,149,000	164,507,000	182,863,000	176,191,000	196,158,000	192,987,000	166,088,000	148,384,000	140,651,000	127,268,000	127,499,000	123,312,000	117,610,000	103,969,000
pharmaceutical and clinical services																				10,700,000	13,500,000	9,500,000	9,900,000	13,500,000	14,000,000	14,300,000	18,500,000	16,100,000	13,800,000	13,300,000	13,200,000	13,800,000	14,800,000	11,400,000	12,600,000	11,700,000	12,600,000	12,400,000	12,700,000	13,100,000	10,700,000	11,600,000	11,018,000	7,007,000	5,244,000	4,330,000
total revenue														177,800,000	156,400,000	179,300,000	164,900,000	160,800,000	167,300,000	189,400,000	173,100,000	145,200,000	93,200,000	164,000,000	195,100,000	186,300,000	215,400,000	216,600,000	216,800,000	202,300,000	194,900,000	193,500,000	194,000,000	190,200,000	200,500,000	196,900,000	196,500,000	177,500,000	186,400,000	190,500,000	193,300,000	183,500,000	189,884,000	179,985,000	184,393,000	168,837,000	188,766,000	182,924,000	204,060,000	202,467,000	174,115,000	156,472,000	149,140,000	133,437,000	132,965,000	129,777,000	122,811,000	110,452,000									61,378,250	87,487,000	84,376,000	73,650,000	166,856,000	61,765,000	56,742,000	48,266,000
cost of molecular diagnostic testing														37,025,000	50,400,000	49,700,000	48,000,000	45,800,000	47,800,000	48,000,000	44,100,000	39,900,000	32,200,000	43,100,000	41,000,000	41,200,000	41,600,000	40,300,000	44,000,000	42,300,000	38,000,000	36,800,000	37,700,000	36,200,000	35,700,000	37,900,000	37,400,000	34,300,000	34,200,000	33,600,000	34,100,000	30,900,000	31,941,000	33,011,000	35,050,000	32,797,000	28,298,000	23,648,000	22,755,000	21,439,000	18,416,000	16,462,000	15,566,000	13,932,000	13,872,000	13,465,000	12,815,000	11,300,000
cost of pharmaceutical and clinical services																				5,700,000	6,200,000	4,300,000	4,500,000	7,000,000	8,600,000	8,500,000	9,000,000	8,300,000	8,100,000	7,400,000	7,800,000	7,300,000	6,700,000	6,800,000	6,900,000	6,400,000	7,000,000	5,700,000	5,800,000	6,600,000	6,500,000	5,600,000	6,448,000	3,282,000	2,802,000	2,068,000
income before income tax														-22,125,000	-44,200,000			-43,500,000	39,800,000				-58,500,000	-131,100,000	-11,400,000	-22,300,000	1,925,000	3,300,000	3,600,000	800,000	10,200,000	16,500,000	3,700,000	86,600,000	18,800,000	8,000,000	12,100,000	4,000,000	37,200,000	43,100,000	45,000,000	43,500,000
net income attributable to non-controlling interest
net income attributable to myriad genetics, inc. stockholders														-17,425,000	-35,100,000			-7,600,000	24,600,000				-55,400,000	-115,200,000	-8,300,000	-20,600,000	-4,200,000	6,900,000	2,600,000	-700,000	6,500,000	11,400,000	32,100,000	81,100,000	12,800,000	4,200,000	5,900,000	-1,200,000
net income per share
basic														-0.218	-0.43			-0.063	0.31
diluted														-0.218	-0.43			-0.063	0.3
weighted-average shares outstanding:
basic															80.7			78	78.8				74.3	74.5	74.4	73.7	73.5	73.3	74.2	73	69.4	69.8	69.3	68.6	68.3	68.1	68.2	68.8	70	70.9	70.5	68.7	71.3	70,696	72,467	72,763	75,728	73,821	75,070	79,575	80,948	80,375	81,692	81,572	84,608	84,403	84,498	85,241	89,794,000	88,206	91,528	93,263	96,338,000	96,853,000	96,270,000	95,970,000	93,492,000	94,327	46,592	45,398	44,189
diluted															80.7			78	81.5				74.3	74.5	74.4	73.7	76	74.9	76.5	73	72	72.4	71.9	70.4	68.8	68.3	68.3	68.8	73.4	73.5	73.8	72.1	74.5	73,870	75,401	76,086	78,182	76,374	76,825	81,798	83,327	82,434	84,240	83,914	86,465	86,462	86,231	87,037	91,704,000	90,127	93,647	94,734	99,152,000	99,674,000	99,426,000	99,492,000	98,573,000	99,594	48,858	48,309	46,704
net loss attributable to non-controlling interest																											-100,000			-100,000		-100,000		-100,000	-100,000
net loss attributable to myriad genetics, inc. stockholders																-14,100,000	-20,500,000			-4,700,000	-39,500,000	-15,200,000
change in the fair value of contingent consideration																		425,000	400,000	400,000	900,000	-1,100,000		-3,400,000	-100,000	700,000	-300,000		1,000,000	400,000	100,000	-1,200,000	13,000,000	-73,200,000	2,800,000	-5,200,000
goodwill and intangible asset impairment charges																								98,400,000
total other income:																							9,800,000	2,600,000							500,000	-500,000	-700,000	-800,000	1,800,000	-4,900,000	-1,100,000	-2,200,000	1,600,000	500,000	-200,000	200,000
income tax provision																							-5,175,000	-15,900,000	-3,100,000	-1,700,000	-3,400,000	-3,600,000	1,000,000	1,600,000	3,700,000	5,200,000	-28,400,000	5,600,000	6,100,000	3,800,000	6,200,000	5,200,000	1,500,000	10,500,000	14,700,000	16,900,000	16,804,000	14,091,000	13,909,000	9,895,000	18,921,000	20,573,000	33,784,000	28,362,000	23,153,000	21,349,000	21,949,000	19,686,000	19,330,000	17,866,000	18,487,000	16,706,000	16,067,000	14,372,000	14,863,000	13,640,000	-14,646,000	1,229,000	980,000	968,000		-94,000		287,000
earnings per share:
basic																							-0.75	-1.55	-0.11	-0.28	-0.06	0.09	0.04	-0.01	0.09	0.16	0.46	1.18	0.19	0.06	0.09	-0.02	0.51	0.46	0.43	0.39	0.27	0.3	0.33	0.22	0.46	0.5	0.67	0.7	0.55	0.47	0.43	0.37	0.35	0.35	0.33	0.29	0.205	0.32	0.26	0.24					0.165	0.27	0.46	0.32
diluted																							-0.75	-1.55	-0.11	-0.28	-0.06	0.09	0.03	-0.01	0.08	0.16	0.45	1.15	0.19	0.06	0.09	-0.02	0.49	0.44	0.41	0.37	0.26	0.29	0.32	0.21	0.43	0.48	0.66	0.68	0.54	0.46	0.42	0.36	0.34	0.34	0.33	0.29	0.2	0.31	0.26	0.24					0.155	0.25	0.43	0.3
total other expense:																									-2,600,000	-1,400,000	-1,375,000	-2,600,000	-2,500,000	-400,000
other income																																											279,250	-298,000	1,513,000
income before income taxes																																											24,846,000	35,566,000	37,940,000	25,877,000	52,553,000	57,343,000	84,144,000	83,827,000	67,227,000	59,241,000	56,985,000	49,822,000	48,472,000	47,481,000	46,783,000	41,805,000	29,386,000	42,312,000	39,054,000	36,178,000
weighted-average shares outstanding
basic															80.7			78	78.8				74.3	74.5	74.4	73.7	73.5	73.3	74.2	73	69.4	69.8	69.3	68.6	68.3	68.1	68.2	68.8	70	70.9	70.5	68.7	71.3	70,696	72,467	72,763	75,728	73,821	75,070	79,575	80,948	80,375	81,692	81,572	84,608	84,403	84,498	85,241	89,794,000	88,206	91,528	93,263	96,338,000	96,853,000	96,270,000	95,970,000	93,492,000	94,327	46,592	45,398	44,189
diluted															80.7			78	81.5				74.3	74.5	74.4	73.7	76	74.9	76.5	73	72	72.4	71.9	70.4	68.8	68.3	68.3	68.8	73.4	73.5	73.8	72.1	74.5	73,870	75,401	76,086	78,182	76,374	76,825	81,798	83,327	82,434	84,240	83,914	86,465	86,462	86,231	87,037	91,704,000	90,127	93,647	94,734	99,152,000	99,674,000	99,426,000	99,492,000	98,573,000	99,594	48,858	48,309	46,704
comprehensive income:
unrealized gain on available-for-sale securities, net of tax																																											-70.5	-6	-145	-132	27	45	253	-285	-525	259	-70	83
change in foreign currency translation adjustment, net of tax																																											-1,420.75	-3,293	-1,669	-721	-1,421	-672	-112	-504	561	-497	-280	208
comprehensive income																																											13,880.75	18,176	22,217	15,129	32,238	36,143	50,501	54,676	44,110	37,654	34,686	30,427
companion diagnostic services																																															6,028,750	6,733,000	7,902,000	9,480,000	8,027,000	8,088,000	8,489,000	6,169,000	5,466,000	6,465,000	5,201,000	6,483,000
cost of companion diagnostic services																																															2,594,750	2,961,000	3,376,000	4,042,000	3,657,000	3,872,000	4,318,000	3,395,000	3,080,000	3,763,000	3,302,000	3,061,000
molecular diagnostic revenue																																																															67,180,000	90,830,000	92,768,000	85,122,000	86,078,000	86,531,000	83,952,000	69,965,000	64,679,000	59,023,000	53,097,000	46,056,000	42,268,000	37,991,000	34,175,000	30,851,000
molecular diagnostic cost of revenue																																																															8,256,000	10,880,000	11,083,000	11,062,000	11,185,000	11,232,000	11,060,000	9,790,000	9,051,000	8,263,000	7,690,000	7,335,000	7,602,000	7,577,000	7,529,000	8,105,000
income from continuing operations before income taxes																																																															38,604,000	34,480,000	36,339,000	31,410,000
income from continuing operations																																																															53,250,000	33,251,000	35,359,000	30,442,000
discontinued operations
loss from discontinued operations
earnings per basic share:
continuing operations																																																															550	340	370	320
earnings per basic share																																																															550	340	370	320
earnings per diluted share:
earnings per diluted share																																																															540	330	360	310
revenue:
research and other revenue																																																																			1,266,000	956,000	424,000	3,685,000	2,177,000	2,742,000	3,645,000
income before taxes																																																																			15,292,000	25,224,000	21,203,000	14,741,000
earnings per share
basic																							-0.75	-1.55	-0.11	-0.28	-0.06	0.09	0.04	-0.01	0.09	0.16	0.46	1.18	0.19	0.06	0.09	-0.02	0.51	0.46	0.43	0.39	0.27	0.3	0.33	0.22	0.46	0.5	0.67	0.7	0.55	0.47	0.43	0.37	0.35	0.35	0.33	0.29	0.205	0.32	0.26	0.24					0.165	0.27	0.46	0.32
diluted																							-0.75	-1.55	-0.11	-0.28	-0.06	0.09	0.03	-0.01	0.08	0.16	0.45	1.15	0.19	0.06	0.09	-0.02	0.49	0.44	0.41	0.37	0.26	0.29	0.32	0.21	0.43	0.48	0.66	0.68	0.54	0.46	0.42	0.36	0.34	0.34	0.33	0.29	0.2	0.31	0.26	0.24					0.155	0.25	0.43	0.3
other income: - sum																																																																							2,609,250	3,185,000	3,669,000	3,583,000	4,462,000	3,155,000	2,573,000	2,575,000	2,557,000	2,383,000	1,648,000	811,000
basic and diluted loss per share																																																																							-0.1	-0.1	-0.11	-0.18	-0.168	-0.14	-0.22	-0.31	-0.19	-0.24	-0.22	-0.3			-0.33		-0.278	-0.39	-0.36	-0.35	-0.175	-0.2	-0.27
basic and diluted weighted-average shares outstanding																																																																								44,448	44,094	43,568	41,055,000	41,503	39,808	39,700	36,278,000	39,232	35,547	30,886	30,720		30,682			27,148	27,109	27,087	25,730,000	27,012	25,081
research revenue																																																																										2,210,000	3,210,000	2,979,000	2,960,000	2,692,000	3,192,000	2,942,000	3,938,000	3,585,000			2,104,000		2,440,250	1,909,000	2,773,000	5,079,000	5,970,000	6,432,000	8,406,000
total revenues																																																																											27,912,000	40,970,000	37,135,000	33,543,000	32,025,000	29,809,000	27,330,000	25,114,000			19,639,000		10,394,000	13,756,000	14,148,000	13,672,000	15,704,000	16,088,000	17,019,000
selling, general and administrative expense																																																																											12,341,250	19,067,000	16,211,000	14,086,000	8,704,500	12,291,000	11,628,000	10,898,000			10,638,000		6,170,000	8,821,000	9,523,000	8,108,000	6,198,750	7,785,000	9,295,000
predictive medicine revenue																																																																															28,833,000	26,867,000	23,392,000	21,529,000			17,535,000		7,552,250	11,699,000	10,446,000	8,064,000	9,354,000	9,314,000	8,151,000
predictive medicine cost of revenue																																																																															8,063,000	7,505,000	6,272,000	5,803,000			5,131,000		2,479,000	3,709,000	3,448,000	2,758,000	3,276,000	3,361,000	2,995,000
related party research revenue																																																																																							401,500	148,000	929,000	529,000	380,000	342,000	462,000
total research revenue																																																																																					2,104,000		2,841,750	2,057,000	3,702,000	5,608,000	6,350,000	6,774,000	8,868,000
loss before taxes																																																																																							-7,539,750	-10,696,000	-9,854,000	-9,609,000
income taxes																																																																																											42,000	125,000	125,000

Balance Sheets:

Quarterly

Annual

Unit: USD	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2004-12-31	2004-06-30	2004-03-31	2003-12-31	2003-09-30	2003-06-30	2003-03-31	2002-12-31	2002-06-30	2001-06-30

assets
current assets:
cash and cash equivalents	124,400,000	149,600,000	145,400,000	74,400,000	91,800,000	102,400,000	99,900,000	92,400,000	96,900,000	132,100,000	76,000,000	102,800,000	53,600,000	56,900,000	110,700,000	105,200,000	165,200,000	258,400,000	295,200,000	118,400,000	148,900,000	118,300,000	163,700,000	121,000,000	81,200,000	89,900,000	93,200,000	84,900,000	90,600,000	93,300,000	110,900,000	97,400,000	88,700,000	87,900,000	102,400,000	123,800,000	108,100,000	86,900,000	68,500,000	120,500,000	134,700,000	87,400,000	64,100,000	55,209,000	59,709,000	69,803,000	64,821,000	85,798,000	71,599,000	84,987,000	104,073,000	112,323,000	68,423,000	95,583,000	86,352,000	104,852,000	108,848,000	62,676,000	52,681,000	67,378,000	67,669,000	123,305,000	92,840,000	102,149,000	60,431,000	91,196,000	63,510,000	200,685,000	178,985,000	230,233,000	237,734,000	142,392,000	114,575,000	107,216,000	143,432,000	194,871,000	85,868,000	88,625,000	98,573,000	106,407,000	118,582,000	38,728,000	49,509,000	62,516,000		46,912,000	42,464,000	48,233,000	61,603,000	80,421,000	97,027,000
trade accounts receivable	123,800,000	115,300,000	118,000,000	137,000,000	120,400,000	121,200,000	125,700,000	117,800,000	118,100,000	114,300,000	115,200,000	111,700,000	119,100,000	101,600,000	102,200,000	109,800,000	101,700,000	91,300,000	93,600,000	94,800,000	94,100,000	85,100,000	68,100,000	102,500,000	118,300,000	117,000,000	133,900,000	142,600,000	116,600,000	119,100,000
inventory	27,900,000	30,600,000	31,600,000	28,700,000	28,300,000	27,500,000	26,200,000	26,100,000	24,600,000	22,000,000	25,100,000	22,500,000	21,800,000	20,100,000	19,600,000	15,400,000	15,600,000	15,300,000	18,600,000	17,700,000	24,600,000	26,600,000	29,100,000	30,800,000	28,100,000	28,100,000	31,400,000	31,900,000	33,300,000	35,900,000	34,300,000	33,400,000	38,200,000	38,900,000	42,200,000	47,400,000	51,300,000	53,900,000	38,300,000	25,300,000	29,100,000	34,300,000	25,100,000	29,359,000	20,173,000	24,775,000	23,919,000	18,906,000			5,007,000	7,136,000	10,467,000	10,602,000	11,574,000	10,383,000	10,294,000	9,703,000	5,668,000
prepaid taxes	2,000,000	12,000,000	13,800,000	14,300,000	14,300,000	16,400,000	17,000,000	18,400,000	18,400,000	17,000,000	17,500,000	17,700,000	17,600,000	17,600,000	17,800,000	19,200,000	18,800,000	18,400,000	400,000	18,600,000	18,100,000	107,900,000		25,400,000	24,700,000	23,000,000	25,100,000	3,000,000	3,100,000	3,600,000		3,700,000	8,400,000	8,800,000	200,000	100,000	4,200,000	5,600,000	3,800,000	15,300,000	28,000,000	13,500,000			5,602,000	18,698,000	13,609,000	12,360,000								10,633,000	16,569,000
prepaid expenses and other current assets	34,700,000	25,100,000	36,000,000	29,900,000	32,400,000	30,500,000	24,400,000	21,600,000	24,900,000	19,400,000	21,300,000	20,800,000	24,400,000	20,400,000	19,500,000	17,600,000	22,900,000	20,000,000	20,200,000	17,700,000
total current assets	312,800,000	332,600,000	344,800,000	284,300,000	287,200,000	298,000,000	293,200,000	291,600,000	290,300,000	313,600,000	265,400,000	294,300,000	261,600,000	274,600,000	352,300,000	367,100,000	427,400,000	484,800,000	498,900,000	538,900,000	329,200,000	394,500,000	331,700,000	355,200,000	365,300,000	329,500,000	348,600,000	342,900,000	336,800,000	341,900,000	326,400,000	331,500,000	327,000,000	325,600,000	317,100,000	348,300,000	341,600,000	322,900,000	314,500,000	372,400,000	375,500,000	307,300,000	283,600,000	282,424,000	320,088,000	335,366,000	322,423,000	338,164,000	454,506,000	458,675,000	483,992,000	447,705,000	457,333,000	435,134,000	422,492,000	418,669,000	432,437,000	418,479,000	418,261,000	415,606,000	444,812,000	491,847,000	473,976,000	450,621,000	400,848,000	410,351,000	366,153,000	456,574,000	376,921,000	365,554,000	377,303,000	252,948,000	229,502,000	232,899,000	343,262,000	334,726,000	234,369,000	237,804,000	252,287,000	254,019,000	261,809,000	127,361,000	135,555,000	109,229,000		93,520,000	91,122,000	98,122,000	102,823,000	121,229,000	133,660,000
operating lease right-of-use assets	51,000,000	49,400,000	50,600,000	51,200,000	53,400,000	55,000,000	57,400,000	56,500,000	58,900,000	61,600,000	104,000,000	106,600,000	107,000,000	103,900,000	110,600,000	82,900,000	70,900,000	81,800,000	83,600,000	86,600,000	58,900,000	62,700,000	66,000,000	64,500,000	67,300,000	71,300,000
property, plant and equipment	111,500,000	114,000,000				117,400,000				119,000,000				83,400,000				43,500,000			45,100,000	36,700,000	37,000,000	37,100,000	36,500,000	55,000,000	57,300,000	58,700,000	59,100,000	60,000,000	43,200,000	48,200,000	48,400,000	49,800,000	51,100,000	53,000,000	54,700,000	56,800,000	58,300,000	60,000,000	61,700,000	64,900,000	67,200,000
intangible assets	145,700,000	153,400,000
goodwill	47,100,000	51,600,000	51,600,000	51,600,000	286,300,000	286,300,000	286,300,000	286,300,000	287,000,000	287,400,000	286,600,000	287,200,000	287,100,000	286,800,000	236,500,000	237,800,000	238,800,000	239,200,000	239,700,000	240,100,000	328,300,000	328,300,000	327,600,000	327,100,000	408,100,000	416,100,000	417,200,000	415,900,000	413,200,000	413,300,000	318,600,000	320,200,000	319,400,000	319,000,000	316,100,000	315,000,000	315,400,000	312,800,000	195,300,000	177,900,000	177,000,000	177,300,000	177,200,000	185,228,000	169,181,000	169,181,000	169,181,000	166,746,000	56,850,000	56,850,000	56,850,000	56,850,000	56,850,000	56,850,000	56,850,000	56,850,000	56,850,000	56,850,000	56,051,000
other assets	5,600,000	5,600,000	6,600,000	7,100,000	7,700,000	8,500,000	16,500,000	14,900,000	14,900,000	15,400,000	15,800,000	22,100,000	17,500,000	15,500,000	8,300,000	8,800,000	8,200,000	8,300,000	8,000,000	4,800,000	3,600,000	1,200,000															2,500,000	5,000,000	5,000,000	5,000,000	5,000,000	5,000,000	5,000,000	5,000,000	5,000,000	5,000,000	5,000,000	5,000,000	13,000,000	13,000,000	13,000,000	8,000,000	8,000,000	8,000,000	8,000,000	8,000,000	8,000,000	8,000,000		1,911,000	1,991,000	1,972,000	333,000	2,133,000	2,214,000	2,194,000	2,275,000	2,480,000	2,592,000	2,604,000	685,000	3,604,000	3,742,000	3,779,000	3,917,000	4,054,000	4,192,000	4,349,000	4,487,000	4,624,000	4,762,000	4,799,000	4,937,000	7,176,000		7,488,000	7,626,000	7,663,000	7,801,000	6,101,000	6,151,000
total assets	673,700,000	706,600,000	728,100,000	677,300,000	1,006,100,000	1,027,600,000	1,081,300,000	1,085,100,000	1,110,500,000	1,146,500,000	1,149,100,000	1,187,200,000	1,169,300,000	1,198,700,000	1,212,000,000	1,210,200,000	1,255,400,000	1,320,700,000	1,335,900,000	1,360,300,000	1,336,900,000	1,444,500,000	1,404,600,000	1,446,700,000	1,578,300,000	1,591,200,000	1,562,700,000	1,557,300,000	1,556,600,000	1,573,600,000	1,174,100,000	1,218,500,000	1,228,500,000	1,228,300,000	1,224,400,000	1,267,800,000	1,276,100,000	1,270,900,000	880,500,000	868,200,000	871,700,000	787,000,000	766,200,000	779,049,000	781,854,000	809,006,000	823,814,000	816,426,000	756,681,000	781,658,000	803,821,000	729,028,000	717,746,000	703,061,000	690,635,000	699,253,000	661,258,000	611,735,000	610,827,000	557,280,000	593,609,000	610,842,000
liabilities and stockholders' equity
current liabilities:
accounts payable	32,600,000	30,000,000	31,800,000	30,900,000	28,100,000	32,300,000	29,600,000	33,300,000	33,100,000	25,800,000	33,900,000	39,800,000	36,500,000	28,800,000	29,600,000	21,700,000	27,100,000	29,600,000	15,700,000	28,500,000	20,800,000	19,100,000	21,700,000	30,300,000	21,000,000	24,000,000	33,300,000	24,100,000	31,900,000	23,800,000	26,000,000	20,200,000	25,100,000	22,500,000	22,000,000	26,800,000	22,900,000	19,900,000	21,100,000	13,800,000	16,500,000	15,800,000	21,100,000	17,955,000	16,833,000	25,728,000	23,078,000	18,935,000	17,596,000	18,745,000	18,132,000	12,238,000	13,575,000	11,086,000	10,141,000	7,939,000	8,876,000	9,827,000	11,395,000	5,191,000	7,050,000	7,242,000	8,870,000	7,026,000	9,403,000	7,648,000	14,177,000	11,426,000	12,771,000	14,999,000	24,884,000	12,009,000	13,910,000	13,993,000	15,763,000	10,998,000	15,197,000	11,650,000	11,804,000	10,492,000	14,708,000	9,720,000	11,897,000	8,309,000		8,927,000	3,890,000	5,809,000	11,454,000	4,653,000	11,609,000
accrued liabilities	90,500,000	96,900,000	108,300,000	100,600,000	112,100,000	119,000,000	111,200,000	98,300,000	99,200,000	113,900,000	157,600,000	164,300,000	91,700,000	94,300,000	85,300,000	84,400,000	124,800,000	156,500,000	163,200,000	90,900,000	83,100,000	65,400,000	75,900,000	63,100,000	61,100,000	73,000,000	78,900,000	78,800,000	73,700,000	76,400,000	68,300,000	64,100,000	60,800,000	59,800,000	65,600,000	64,000,000	57,700,000	54,800,000	49,500,000	50,800,000	47,900,000	41,800,000	46,100,000	47,879,000	41,180,000	40,654,000	56,410,000	51,103,000	45,844,000	59,390,000	44,334,000	38,352,000	29,192,000	42,995,000	32,772,000	27,726,000	23,736,000	20,383,000	21,645,000	18,181,000	16,138,000	23,689,000	18,596,000	15,191,000	13,308,000	13,345,000	17,992,000	25,019,000	40,820,000	39,177,000	46,770,000	23,594,000	20,647,000	17,620,000	15,558,000	11,555,000	10,841,000	11,239,000	14,901,000	9,999,000	7,583,000	8,628,000	10,136,000	7,432,000		4,224,000	6,779,000	4,026,000	4,925,000	4,342,000	4,137,000
current maturities of operating lease liabilities	7,100,000	6,900,000	7,900,000	9,000,000	10,900,000	12,800,000	13,500,000	13,300,000	13,800,000	16,200,000	17,800,000	17,000,000	15,100,000	14,100,000	14,000,000	13,300,000	13,400,000	13,000,000	12,800,000	12,700,000	14,000,000	13,600,000	13,500,000	12,900,000	12,800,000	13,000,000
total current liabilities	130,200,000	133,800,000	148,000,000	199,900,000	151,100,000	164,100,000	154,300,000	148,900,000	146,100,000	155,900,000	209,300,000	221,100,000	143,300,000	137,200,000	129,100,000	119,700,000	166,000,000	204,300,000	203,200,000	271,000,000	149,000,000	133,700,000	147,000,000	113,200,000	112,400,000	115,400,000	117,800,000	108,900,000	113,300,000	108,000,000	102,200,000	94,300,000	159,300,000	139,200,000	217,500,000	221,700,000	82,800,000	274,900,000	72,300,000	66,100,000	65,900,000	59,000,000	68,700,000	67,173,000	59,837,000	67,725,000	80,578,000	72,156,000	67,392,000	79,030,000	64,509,000	53,621,000	45,488,000	57,356,000	44,967,000	37,052,000	35,046,000	31,293,000	34,387,000	23,372,000	23,188,000	30,931,000	27,466,000	22,217,000	22,711,000	20,993,000	32,202,000	36,503,000	53,821,000	54,184,000	73,687,000	37,661,000	34,890,000	31,622,000	31,704,000	22,960,000	26,472,000	22,947,000	26,822,000	21,593,000	23,583,000	22,347,000	23,285,000	17,359,000		14,840,000	12,890,000	12,210,000	19,337,000	12,919,000	21,669,000
long-term debt	120,300,000	119,900,000	119,500,000		59,300,000	39,600,000	39,000,000	38,800,000	38,700,000	38,500,000	38,500,000	38,400,000									154,000,000	224,600,000	224,400,000	225,200,000	225,100,000	225,000,000	233,500,000	263,400,000	273,300,000	258,000,000	9,300,000	69,300,000	43,200,000	74,200,000	99,100,000	167,100,000	204,000,000
noncurrent operating lease liabilities	84,100,000	83,000,000	84,900,000	86,200,000	87,400,000	87,900,000	90,600,000	91,200,000	94,300,000	97,400,000	145,100,000	148,400,000	146,500,000	130,900,000	123,300,000	87,400,000	76,500,000	79,300,000	80,700,000	83,900,000	49,400,000	53,500,000	56,900,000	55,900,000	58,700,000	62,600,000
other long-term liabilities	1,700,000	1,700,000	1,700,000	1,900,000	2,000,000	2,200,000	34,300,000	34,600,000	40,600,000	41,300,000	40,500,000	11,400,000	11,500,000	14,500,000	4,600,000	4,700,000	4,900,000	5,600,000	10,800,000	13,800,000	19,300,000	10,700,000	4,300,000			7,300,000	7,800,000	7,300,000	6,600,000	6,300,000	6,300,000	6,800,000	6,600,000	7,400,000	7,200,000	7,200,000	8,800,000	148,700,000	18,200,000	7,700,000	6,800,000	7,100,000	8,800,000
total liabilities	336,300,000	338,600,000	355,300,000	289,200,000	301,200,000	326,500,000	349,600,000	344,600,000	350,500,000	363,300,000	465,700,000	452,000,000	334,100,000	312,900,000	295,400,000	262,800,000	305,300,000	352,900,000	367,400,000	457,900,000	461,700,000	535,200,000	486,400,000	479,500,000	501,000,000	516,700,000	473,800,000	475,600,000	492,500,000	471,400,000	209,200,000	270,100,000	314,300,000	357,700,000	446,600,000	519,900,000	543,400,000	535,600,000	132,400,000	98,000,000	100,900,000	99,900,000	104,100,000	110,151,000	87,613,000	96,856,000	104,816,000	94,184,000	80,710,000	91,386,000	75,227,000	64,099,000	55,626,000	67,494,000	54,975,000	47,060,000	44,494,000	40,741,000	44,035,000	32,820,000	32,508,000	39,731,000	36,266,000
commitments and contingencies
stockholders’ equity:
common stock	900,000		900,000	900,000	900,000		900,000	900,000	900,000		800,000	800,000	800,000		800,000	800,000	800,000		800,000	800,000	800,000	800,000	700,000	700,000	700,000	700,000	700,000	700,000	700,000	700,000	700,000	700,000	700,000	700,000	700,000	700,000	700,000	700,000	700,000	700,000	700,000	700,000	700,000																												447,000				434,000				397,000				309,000						271,000
additional paid-in capital	1,492,600,000	1,489,000,000	1,486,800,000	1,474,700,000	1,461,500,000	1,457,800,000	1,445,200,000	1,435,800,000	1,418,800,000	1,415,500,000	1,286,200,000	1,276,800,000	1,262,700,000	1,260,100,000	1,251,000,000	1,244,300,000	1,231,600,000	1,226,300,000	1,218,800,000	1,176,900,000	1,144,500,000	1,101,200,000	1,096,600,000	1,092,800,000	1,085,100,000	1,076,300,000	1,068,000,000	1,057,000,000	1,045,600,000	1,052,400,000	915,400,000	889,600,000	871,100,000	859,600,000	851,400,000	839,500,000	831,800,000	826,900,000	830,100,000	847,000,000	847,800,000	772,300,000	745,400,000	738,040,000	734,679,000	731,238,000	717,774,000	702,754,000	663,122,000	675,184,000	697,346,000	662,541,000	665,800,000	649,621,000	647,680,000	651,535,000	637,605,000	616,560,000	604,409,000	571,585,000	580,762,000	573,683,000	566,967,000	586,102,000	568,646,000	559,000,000	550,432,000	725,897,000	687,731,000	673,294,000	630,000,000	621,682,000	613,973,000	601,645,000	592,727,000	583,488,000	474,391,000	469,736,000	467,568,000	463,058,000	458,370,000	316,510,000	315,147,000	313,410,000		261,762,000	261,637,000	261,195,000	261,155,000	260,591,000	260,577,000
accumulated other comprehensive income	700,000	800,000																														1,800,000																-122,000	506,000	365,000				129,000	-162,000	-99,000	-253,000	-113,000	151,000	100,000	99,000	262,000	139,000	1,155,000	1,854,000	2,672,000	2,768,000	656,000	446,000			1,264,000	516,000	63,000												265,000	311,000	560,000	711,000	707,000	631,000
accumulated deficit	-1,156,800,000	-1,122,700,000	-1,114,800,000	-1,087,400,000	-756,900,000	-756,800,000	-714,300,000	-692,200,000	-655,500,000	-629,500,000	-598,300,000	-537,000,000	-420,900,000	-366,200,000	-323,900,000	-288,800,000	-274,700,000	-254,200,000	-246,600,000	-271,200,000	-266,500,000	-189,100,000													-68,400,000	-81,400,000	-85,700,000	-86,500,000	-73,200,000	-69,200,000	-68,600,000	-78,800,000											-4,272,000	-14,997,000	-12,684,000	-88,000	-21,430,000	-38,299,000	-38,630,000	-48,082,000	-20,661,000	-3,758,000	-10,465,000	-20,887,000	-54,138,000	-89,498,000	-119,940,000	-143,580,000	-168,898,000	-190,101,000	-204,555,000	-270,096,000	-265,465,000	-260,399,000	-252,400,000	-244,596,000	-238,659,000	-229,863,000	-217,438,000	-206,014,000	-196,443,000	-188,491,000	-179,249,000			-128,810,000	-118,114,000	-108,260,000	-98,651,000
total stockholders' equity	337,400,000	368,000,000	372,800,000	388,100,000	704,900,000	701,100,000	731,700,000	740,500,000	760,000,000	783,200,000	683,400,000	735,200,000	835,200,000	885,800,000	916,600,000	947,400,000	950,100,000	967,800,000	968,500,000	902,400,000	875,200,000	909,300,000	918,200,000	967,200,000	1,077,300,000	1,074,500,000	1,088,900,000	1,081,700,000	1,064,100,000	1,102,200,000	964,900,000	948,400,000	914,200,000	870,600,000	777,800,000	747,900,000
total liabilities and stockholders’ equity	673,700,000	706,600,000	728,100,000	677,300,000	1,006,100,000	1,027,600,000	1,081,300,000	1,085,100,000	1,110,500,000	1,146,500,000	1,149,100,000	1,187,200,000	1,169,300,000	1,198,700,000	1,212,000,000	1,210,200,000	1,255,400,000	1,320,700,000	1,335,900,000	1,360,300,000	1,336,900,000	1,444,500,000	1,404,600,000	1,446,700,000	1,578,300,000	1,591,200,000	1,562,700,000	1,557,300,000	1,556,600,000	1,573,600,000	1,174,100,000	1,218,500,000	1,228,500,000	1,228,300,000	1,224,400,000	1,267,800,000	1,276,100,000	1,270,900,000	880,500,000	868,200,000	871,700,000	787,000,000	766,200,000	779,049,000	781,854,000	809,006,000	823,814,000				803,821,000				690,635,000				610,827,000
unrecognized tax benefits		200,000	1,200,000	1,200,000	1,400,000	32,700,000	31,400,000	31,100,000	30,800,000	30,200,000	29,600,000	29,000,000	28,700,000	26,800,000	27,900,000	27,700,000	28,000,000	27,900,000	32,000,000	31,000,000	30,800,000	37,400,000	23,500,000	22,300,000	22,400,000	22,100,000	21,700,000	19,900,000	24,900,000	24,600,000	24,900,000	27,900,000	33,400,000	31,900,000	25,200,000	24,900,000	24,600,000	24,400,000	24,000,000	24,000,000	27,900,000	27,200,000	26,400,000	26,111,000	25,326,000	24,514,000	24,238,000	13,641,000	13,318,000	12,356,000	10,718,000	10,478,000	10,138,000	10,138,000	10,008,000	10,008,000	9,448,000	9,448,000	9,648,000	9,448,000	9,320,000	8,800,000	8,800,000
common stock, 0.01 par value...		900,000				900,000				900,000				800,000				800,000																										700,000	719,000	729,000	735,000	745,000	740,000	768,000	806,000	797,000	813,000	814,000	826,000	845,000	842,000	846,000	862,000	857,000	901,000	924,000	940,000	976,000	964,000	962,000	959,000	954,000	467,000	464,000		446,000	444,000	439,000		430,000	399,000	397,000		394,000	391,000	309,000		307,000		272,000	271,000	271,000		270,000	270,000
property, plant, and equipment			111,400,000	113,000,000	114,000,000		115,400,000	116,300,000	118,500,000		120,700,000	112,000,000	96,300,000		67,500,000	52,800,000	45,700,000		43,400,000	43,200,000
intangibles			163,100,000	170,100,000	257,500,000	262,400,000	312,500,000	319,500,000	340,900,000	349,500,000	356,600,000	358,800,000	369,400,000	379,700,000	370,800,000	382,300,000	393,600,000	404,100,000	414,800,000	426,800,000	559,900,000	590,900,000	605,300,000	620,000,000	653,500,000	667,800,000	684,700,000	699,500,000	717,600,000	734,200,000	455,200,000	467,300,000	475,200,000	483,800,000	491,600,000	498,100,000	506,400,000	521,200,000	227,500,000	183,200,000	186,300,000	189,400,000	192,600,000	195,691,000	198,827,000	201,962,000	205,312,000	208,296,000	12,842,000	13,086,000	13,330,000	13,525,000	13,719,000	15,447,000	15,722,000	15,990,000	16,265,000	16,440,000	16,715,000
accumulated other comprehensive loss			-100,000	-100,000	-600,000	-800,000	-100,000	-4,000,000	-4,200,000	-3,700,000	-5,300,000	-5,400,000	-7,400,000	-8,900,000	-11,300,000	-8,900,000	-7,600,000	-5,100,000	-4,400,000	-4,000,000	-3,600,000	-3,600,000	-5,200,000	-7,800,000	-5,300,000	-7,500,000	-5,400,000	-5,700,000	-5,000,000	-4,300,000	-4,100,000		-2,400,000	-2,200,000	-5,500,000	-10,600,000	-13,900,000	-5,600,000	-9,500,000	-8,300,000	-9,100,000	-7,100,000	-7,000,000	-7,560,000	-4,182,000	-2,368,000	-1,515,000				-424,000	-459,000	-221,000																	-6,613,000	-237,000				-398,000	-133,000	-281,000	-401,000	-746,000	-738,000	-672,000	-640,000	-534,000
current debt				59,400,000
marketable investment securities								4,900,000	7,400,000	8,800,000	10,300,000	18,800,000	25,100,000	58,000,000	82,500,000	99,900,000	103,200,000	81,400,000	70,900,000	46,000,000	27,200,000	42,100,000	54,100,000	60,500,000	60,400,000	52,700,000	43,700,000	64,800,000	74,800,000	74,200,000	69,700,000	59,900,000	54,800,000	60,400,000	48,300,000	48,300,000	54,400,000	61,500,000	90,500,000	96,200,000	84,600,000	68,000,000	80,700,000	79,224,000	105,406,000	89,807,000	121,641,000	126,360,000	281,996,000	272,031,000	268,243,000	223,834,000	290,210,000	253,582,000	254,180,000	232,512,000	241,782,000	286,845,000	293,776,000	293,846,000	323,630,000	305,033,000	310,388,000	296,500,000	284,978,000	266,433,000	253,345,000	201,400,000	153,009,000	78,107,000	90,994,000	61,802,000	66,576,000	81,348,000	164,880,000	109,476,000	117,643,000	123,490,000	129,171,000	122,927,000	116,497,000	64,269,000	64,334,000	23,441,000		22,499,000	21,257,000	21,473,000	11,172,000	12,833,000	13,404,000
assets held for sale								10,400,000												225,700,000					32,900,000
liabilities held for sale								4,000,000												12,200,000					10,500,000
long-term marketable investment securities												6,200,000	30,400,000	54,800,000	66,000,000	78,500,000	70,800,000	59,000,000	47,500,000	19,900,000	11,900,000	30,200,000	37,000,000	42,800,000	47,600,000	51,500,000	54,900,000	40,300,000	29,900,000	24,200,000	30,700,000	51,300,000	58,500,000	50,100,000	48,500,000	53,400,000	55,500,000	52,200,000	79,900,000	69,700,000	66,200,000	43,100,000	40,600,000	41,200,000	42,300,000	54,073,000	84,124,000	65,555,000	135,187,000	158,566,000	158,748,000	126,120,000	109,636,000	117,125,000	113,692,000	129,346,000	77,629,000	52,182,000	70,857,000	90,267,000	103,106,000	80,064,000	85,154,000	112,534,000	112,150,000	59,370,000	75,370,000	132,757,000	164,928,000	134,285,000	91,328,000	106,294,000	122,302,000	110,726,000										38,706,000		29,672,000	39,625,000	41,357,000	53,517,000	37,301,000	38,680,000
long-term deferred taxes											2,700,000	3,700,000	4,100,000	3,500,000	10,500,000	23,300,000	29,900,000	35,800,000	40,700,000	58,200,000	59,200,000	75,300,000	26,600,000	59,300,000	75,500,000	76,900,000	82,600,000	65,800,000	64,000,000	64,900,000	57,300,000	62,200,000	60,800,000	91,200,000	84,400,000	84,700,000	86,100,000	87,600,000	17,900,000	200,000	300,000	6,600,000		407,000			3,180,000		29,983,000	28,473,000	28,632,000	28,953,000	24,590,000	26,081,000	30,648,000	27,964,000	28,081,000	27,525,000	25,863,000	28,153,000	20,795,000	13,416,000	9,404,000
total myriad genetics, inc. stockholders' equity														885,800,000				967,800,000					918,200,000				1,088,900,000				964,900,000				778,200,000
non-controlling interest																			-100,000	-100,000					100,000			-100,000	-100,000			100,000		-300,000	-400,000	-300,000	-200,000	-200,000
deferred revenues															200,000	300,000	700,000		11,500,000	22,600,000
total myriad genetics, inc. stockholders’ equity															916,600,000	947,400,000	950,100,000		968,600,000	902,500,000	875,200,000	909,300,000		967,200,000	1,077,200,000	1,074,500,000		1,081,800,000	1,064,200,000	1,102,200,000		948,300,000	914,200,000	870,900,000		748,200,000	732,900,000
deferred revenue																		5,200,000			31,100,000	32,300,000	32,800,000	3,800,000	3,600,000	2,100,000	2,200,000	2,300,000	2,400,000	2,500,000	2,600,000	2,600,000	3,400,000	2,900,000	2,600,000	2,700,000	2,200,000	1,000,000	1,700,000	1,500,000	1,500,000	1,400,000	1,500,000	1,339,000	1,824,000	1,343,000	1,090,000	2,118,000	3,952,000	895,000	2,043,000	3,031,000	2,721,000	3,275,000	2,054,000	1,387,000	2,434,000	1,083,000	1,347,000								33,000	58,000	230,000	8,000	2,033,000	2,058,000	333,000	9,000	383,000	407,000	434,000	58,000	117,000	1,102,000	1,292,000	3,999,000	1,252,000	1,618,000		1,689,000	2,221,000	2,375,000	2,958,000	3,924,000	5,923,000
current portion of long-term debt																				104,100,000
prepaid expenses																					13,900,000	12,500,000	13,800,000	12,500,000	16,200,000	14,000,000	16,600,000	11,300,000	12,500,000	11,500,000	9,400,000	10,100,000	9,800,000	9,500,000	12,700,000	9,500,000	12,100,000	12,200,000	18,400,000	21,100,000	9,700,000	5,600,000	12,500,000	9,985,000	7,694,000	9,419,000	6,921,000	2,307,000	4,237,000	4,857,000	956,000	1,541,000	2,327,000	2,516,000	1,713,000	2,154,000	3,087,000	3,313,000	5,499,000	2,235,000	3,590,000	5,000,000	4,054,000	2,909,000	5,931,000	7,911,000	3,993,000	2,811,000	2,749,000	3,102,000	3,143,000	7,032,000	7,283,000	8,288,000	2,499,000	2,788,000	3,932,000	1,781,000	2,326,000	3,097,000	6,737,000	4,639,000	3,331,000	5,236,000		8,361,000	8,532,000	7,639,000	7,740,000	5,904,000	7,174,000
other receivables																					2,400,000	2,000,000	2,900,000	2,500,000	3,500,000	4,800,000	4,700,000	4,400,000	5,900,000	4,300,000	3,800,000	3,300,000	6,000,000	6,900,000	5,700,000	4,400,000	3,900,000	4,600,000	3,300,000	2,900,000	5,100,000	1,600,000	1,900,000	2,992,000	5,331,000	11,244,000	3,770,000	3,226,000	3,463,000	1,814,000	3,373,000	2,187,000	988,000	1,970,000	2,660,000	1,501,000	1,083,000	655,000	575,000	1,284,000	336,000	387,000		946,000	739,000	1,075,000	688,000	4,205,000	746,000	7,178,000	4,769,000	2,018,000	2,600,000	2,559,000	1,348,000	2,130,000	2,920,000	746,000	1,397,000	1,074,000	1,014,000	978,000	1,145,000	755,000		932,000	5,099,000	8,228,000	9,241,000	10,246,000	6,618,000
short-term contingent consideration																						3,300,000	3,100,000	3,100,000	3,400,000	3,300,000	3,400,000	3,700,000	5,300,000	5,300,000	5,300,000	7,400,000	70,000,000	54,000,000	127,300,000	128,200,000
contingent consideration																							3,700,000	3,600,000	6,900,000	7,400,000	10,400,000	10,300,000	10,400,000	9,600,000	9,200,000	9,600,000	11,000,000	13,800,000	13,200,000	14,300,000	137,100,000
retained earnings																							-173,900,000	-118,500,000	-3,300,000	5,000,000	25,600,000	29,800,000	22,900,000	53,400,000	52,900,000	56,200,000	44,800,000	12,800,000									-77,000,000				2,004,000	18,865,000	11,603,000	13,955,000	30,866,000	2,050,000
trade accounts receivable, less allowance for doubtful accounts of 12.1 in 2018 and 7.6 in 2017																															98,300,000
trade accounts receivable, less allowance for doubtful accounts of 10.3 march 31, 2018 and 8.2 june 30, 2017																																123,700,000
trade accounts receivable, less allowance for doubtful accounts of 9.5 december 31, 2017 and 8.2 june 30, 2017																																	121,100,000
trade accounts receivable, less allowance for doubtful accounts of 8.6 september 30, 2017 and 8.2 june 30, 2017																																		113,200,000
trade accounts receivable, less allowance for doubtful accounts of 8.2 in 2017 and 6.8 in 2016																																			105,600,000
trade accounts receivable, less allowance for doubtful accounts of 8.1 march 31, 2017 and 6.8 june 30, 2016																																				114,800,000
trade accounts receivable, less allowance for doubtful
accounts of 7.8 december 31, 2016 and 6.8 june 30, 2016																																					107,600,000
liabilities and stockholders’ equity
total stockholders’ equity																																					732,700,000	735,300,000	748,100,000	770,200,000	770,800,000	687,100,000	662,100,000	668,898,000	694,241,000	712,150,000	718,998,000	722,242,000	675,971,000	690,272,000	728,594,000	664,929,000	662,120,000	635,567,000	635,660,000	652,193,000	616,764,000	578,994,000	566,792,000	524,460,000	561,101,000	571,111,000	557,581,000	567,346,000	517,326,000	473,136,000	434,219,000	583,927,000	519,746,000	477,044,000	425,655,000	353,296,000	349,468,000	341,748,000	340,363,000	339,189,000	235,850,000	239,869,000	249,781,000	256,700,000	261,646,000	127,688,000	135,673,000	154,003,000		133,489,000	144,105,000	153,766,000	163,486,000	169,998,000	175,441,000
trade accounts receivable, less allowance for doubtful accounts of 6.8 september 30, 2016 and 6.8 june 30, 2016																																						98,200,000
short-term debt																																						199,200,000
total myriad genetic, inc. stockholders’ equity																																						735,500,000
trade accounts receivable, less allowance for doubtful accounts of 6.8 in 2016 and 7.6 in 2015																																							91,700,000
deferred taxes																																										13,500,000	13,500,000	13,460,000	12,813,000	13,229,000	6,445,000	6,529,000	9,074,000	8,768,000	8,007,000	7,512,000	9,354,000	8,378,000	5,572,000	5,686,000	7,786,000	10,469,000	9,790,000	4,427,000	9,524,000	14,293,000	18,560,000
trade accounts receivable, less allowance for doubtful accounts of 6.5 march 31, 2016 and 7.6 june 30, 2015																																								91,100,000
trade accounts receivable, less allowance for doubtful accounts of 6.2 december 31, 2015 and 7.6 june 30, 2015																																									84,300,000
trade accounts receivable, less allowance for doubtful accounts of 6.2 september 30, 2015 and 7.6 june 30, 2015																																										83,400,000
trade accounts receivable, less allowance for doubtful accounts of 7.6 in 2015 and 9.0 in 2014																																											85,800,000
trade accounts receivable, less allowance for doubtful accounts of 7,730 at march 31, 2015 and 8,968 at june 30, 2014																																												92,195,000
equipment, leasehold improvements and property:
equipment																																												97,595,000	95,349,000	89,748,000	80,685,000	76,879,000	73,570,000	70,764,000	65,903,000	62,828,000	61,427,000	57,152,000	54,728,000	52,991,000	50,931,000	48,725,000	46,912,000	51,844,000	51,875,000	50,900,000	48,941,000	48,914,000	48,557,000	48,076,000	49,116,000	67,362,000	65,785,000	63,340,000	63,095,000	61,515,000	61,270,000	56,911,000	54,868,000	52,519,000	53,337,000	49,477,000	47,255,000	45,609,000	43,185,000	40,943,000	40,160,000	35,513,000		33,555,000	33,260,000	32,330,000	31,826,000	30,397,000	29,748,000
leasehold improvements																																												18,956,000	18,913,000	18,840,000	18,922,000	18,654,000	18,390,000	18,340,000	18,294,000	18,246,000	18,167,000	18,054,000	17,800,000	17,773,000	18,266,000	17,409,000	17,201,000	16,438,000	16,385,000	16,332,000	16,332,000	16,222,000	15,590,000	12,011,000	11,942,000	11,895,000	11,856,000	11,738,000	11,701,000	10,750,000	10,145,000	9,974,000	9,826,000	9,821,000	9,358,000	8,450,000	8,331,000	8,200,000	8,157,000	8,092,000	8,004,000	7,760,000		7,643,000	7,626,000	7,605,000	7,531,000	7,469,000	7,374,000
property																																												20,075,000
equipment, leasehold improvements and property: - sum																																												136,626,000
less accumulated depreciation																																												67,527,000	67,804,000	65,164,000	65,013,000	62,868,000	60,647,000	58,429,000	56,595,000	54,199,000	52,309,000	50,449,000	48,297,000	46,663,000	44,868,000	42,875,000	41,033,000	46,939,000	45,355,000	43,689,000	42,012,000	40,861,000	39,322,000	37,873,000	38,435,000	50,638,000	48,515,000	46,293,000	44,770,000	44,154,000	42,603,000	40,919,000	39,806,000
net equipment, leasehold improvements and property																																												69,099,000
deferred grants																																												10,447,000
other long term liabilities																																												6,420,000
preferred stock, 0.01 par value...
accumulated (deficit)/retained earnings																																												-62,282,000	-36,975,000	-17,449,000
restricted cash																																													22,138,000	22,674,000
trade accounts receivable, less allowance for doubtful accounts of 7,929 at december 31, 2014 and 8,968 at june 30, 2014																																													81,222,000
equipment and leasehold improvements:
equipment and leasehold improvements: - sum																																													114,262,000	108,588,000	99,607,000	95,533,000	91,960,000	89,104,000	84,197,000	81,074,000	79,594,000	75,206,000	72,528,000	70,764,000	69,197,000	66,134,000	64,113,000	68,282,000	68,260,000	67,232,000	65,273,000	65,136,000	64,147,000	60,087,000	61,058,000	79,257,000	77,641,000	75,078,000	74,796,000	72,265,000	71,415,000	66,885,000	64,694,000	62,340,000	62,695,000	57,927,000	55,586,000	53,809,000	51,342,000	49,035,000	48,164,000	43,273,000		41,198,000	40,886,000	39,935,000	39,357,000	37,866,000	37,122,000
net equipment and leasehold improvements																																													46,458,000	43,424,000	34,594,000	32,665,000	31,313,000	30,675,000	27,602,000	26,875,000	27,285,000	24,757,000	24,231,000	24,101,000	24,329,000	23,259,000	23,080,000	21,343,000	22,905,000	23,543,000	23,261,000	24,275,000	24,825,000	22,214,000	22,623,000	28,619,000	29,126,000	28,785,000	30,026,000	28,111,000	28,812,000	25,966,000	24,888,000	23,369,000	23,761,000	20,663,000	19,829,000	19,650,000	18,658,000	17,875,000	18,466,000	16,251,000		17,649,000	18,622,000	18,834,000	18,682,000	18,286,000	18,619,000
trade accounts receivable, less allowance for doubtful accounts of 8,382 at september 30, 2014 and 8,968 at june 30, 2014																																														75,717,000
trade accounts receivable, less allowance for doubtful accounts of 8,968 in 2014 and 7,500 in 2013																																															81,297,000
note receivable																																																	23,000,000	22,333,000	21,667,000	21,000,000	20,333,000	19,667,000	19,000,000	18,333,000	17,667,000	17,000,000
trade accounts receivable, less allowance for doubtful accounts of 9,750 at march 31, 2014 and 7,500 at june 30, 2013																																																82,678,000
deferred tax liabilities																																																8,387,000
trade accounts receivable, less allowance for doubtful accounts of 9,200 at dec. 31, 2013 and 7,500 at jun. 30, 2013																																																	84,137,000
trade accounts receivable, less allowance for doubtful accounts of 8,900 at sep. 30, 2013 and 7,500 at jun. 30, 2013																																																		86,218,000
trade accounts receivable, less allowance for doubtful accounts of 7,500 in 2013 and 4,600 in 2012																																																			94,333,000
trade accounts receivable, less allowance for doubtful accounts of 6,300 at mar. 31, 2013 and 4,600 at jun. 30, 2012																																																				93,172,000
trade accounts receivable, less allowance for doubtful accounts of 5,300 at dec. 31, 2012 and 4,600 at jun. 30, 2012																																																					75,564,000
trade accounts receivable, less allowance for doubtful accounts of 5,000 at sept. 30, 2012 and 4,600 at jun. 30, 2012																																																						62,503,000
trade accounts receivable, less allowance for doubtful accounts of 4,600 in 2012 and 3,700 in 2011																																																							60,441,000
trade accounts receivable, less allowance for doubtful accounts of 4,300 at mar. 31, 2012 and 3,700 at jun. 30, 2011																																																								50,948,000
trade accounts receivable, less allowance for doubtful accounts of 4,000 at dec. 31, 2011 and 3,700 at jun. 30, 2011																																																									42,988,000
trade accounts receivable, less allowance for doubtful accounts of 3,700 at sep. 30, 2011 and 3,700 at jun. 30, 2011																																																										44,818,000
trade accounts receivable, less allowance for doubtful accounts of 3,700 in 2011 and 4,400 in 2010																																																											50,272,000
trade accounts receivable, less allowance for doubtful accounts of 4,200 at mar. 31, 2011 and 4,400 at jun. 30, 2010																																																												46,436,000
trade accounts receivable, less allowance for doubtful accounts of 4,200 at dec. 31, 2010 and 4,400 at jun. 30, 2010																																																													40,063,000
trade accounts receivable, less allowance for doubtful accounts of 4,200 at sep. 30, 2010 and 4,400 at jun. 30, 2010																																																														43,829,000
trade accounts receivable, less allowance for doubtful accounts of 4,400 in 2010 and 3,850 in 2009																																																															47,801,000
trade accounts receivable, less allowance for doubtful accounts of 4,400 at mar. 31, 2010 and 3,850 at jun. 30, 2009																																																																48,117,000
trade accounts receivable, less allowance for doubtful accounts of 4,400 at dec. 31, 2009 and 3,850 at jun. 30, 2009																																																																	48,769,000
trade accounts receivable, less allowance for doubtful accounts of 4,000 at sep. 30, 2009 and 3,850 at jun. 30, 2009																																																																		43,736,000
trade accounts receivable, less allowance for doubtful accounts of 3,850 in 2009 and 4,100 in 2008																																																																			44,617,000
trade accounts receivable, less allowance for doubtful accounts of 4,600 at mar. 31, 2009 and 4,100 at jun. 30, 2008																																																																				47,473,000
trade accounts receivable, less allowance for doubtful accounts of 4,600 at dec. 31, 2008 and 4,100 at jun. 30, 2008																																																																					41,432,000
trade accounts receivable, less allowance for doubtful accounts of 4,400 at sep. 30, 2008 and 4,100 at jun. 30, 2008																																																																						46,934,000
trade accounts receivable, less allowance for doubtful accounts of 4,100 in 2008 and 2,600 in 2007																																																																							40,663,000
preferred stock, 0.01 par value. authorized 5,000 shares; issued and outstanding no shares
trade accounts receivable, less allowance for doubtful accounts of 3,950 at mar. 31, 2008 and 2,600 at jun. 30, 2007																																																																								39,704,000
trade accounts receivable, less allowance for doubtful accounts of 3,650 at dec. 31, 2007 and 2,600 at jun. 30, 2007.																																																																									38,468,000
trade accounts receivable, less allowance for doubtful accounts of 2,900 at sep. 30, 2007 and 2,600 at jun. 30, 2007.																																																																										33,488,000
trade accounts receivable, less allowance for doubtful accounts of 2,600 in 2007 and 1,795 in 2006																																																																											31,103,000
trade accounts receivable, less allowance for doubtful accounts of 2,350 at mar. 31, 2007 and 1,795 at june 30, 2006																																																																												25,461,000
less accumulated depreciation and amortization																																																																												38,971,000	38,934,000	37,264,000	35,757,000	34,159,000	32,684,000	31,160,000	29,698,000	27,022,000		23,549,000	22,264,000	21,101,000	20,675,000	19,580,000	18,503,000
trade accounts receivable, less allowance for doubtful accounts of 2,150 at dec. 31, 2006 and 1,795 at june 30, 2006																																																																													24,006,000
trade accounts receivable, less allowance for doubtful accounts of 1,950 at sep. 30, 2006 and 1,795 at june 30, 2006																																																																														23,162,000
trade accounts receivable, less allowance for doubtful accounts of 1,795 in 2006 and 1,395 in 2005, respectively																																																																															20,820,000
trade accounts receivable, less allowance for doubtful accounts of 1,795 at mar. 31, 2006 and 1,395 at june 30, 2005																																																																																20,514,000
trade accounts receivable, less allowance for doubtful accounts of 1,645 at dec. 31, 2005 and 1,395 at june 30, 2005																																																																																	18,979,000
trade accounts receivable, less allowance for doubtful accounts of 1,595 at sep. 30, 2005 and 1,395 at june 30, 2005																																																																																		18,747,000
trade accounts receivable, less allowance for doubtful accounts of 1,395 in 2005 and 1,205 in 2004																																																																																			17,236,000
trade accounts receivable, less allowance for doubtful accounts of 1,495 at dec. 31, 2004 and 1,205 at june 30, 2004																																																																																				17,281,000
stockholders' equity:
trade accounts receivable, less allowance for doubtful accounts of 985 at mar. 31, 2004 and 895 at june 30, 2003																																																																																						14,816,000
related party receivables																																																																																							576,000	176,000	150,000	119,000	98,000
trade accounts receivable, less allowance for doubtful accounts of 880 at dec. 31, 2003 and 895 at june 30, 2003																																																																																							13,194,000
preferred stock, 0.01 par value. 5,000 shares authorized, no shares issued and outstanding
trade accounts receivable, less allowance for doubtful accounts of 805 at sep. 30, 2003 and 895 at june 30, 2003																																																																																								12,373,000
trade accounts receivable, less allowance for doubtful accounts of 895 in 2003 and 505 in 2002																																																																																									12,917,000
related party payable
preferred stock, 0.01 par value. authorized 5,000 shares; no shares issued and outstanding
trade accounts receivable, less allowance for doubtful accounts of 795 at mar. 31, 2003 and 505 at june 30, 2002																																																																																										11,706,000
trade accounts receivable, less allowance for doubtful accounts of 675 at dec. 31, 2002 and 505 at june 30, 2002																																																																																											9,339,000

Cashflow Statements:

Quarterly

Annual

Unit: USD	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2004-03-31	2003-12-31	2003-09-30	2003-06-30	2003-03-31

cash flows from operating activities:
net loss	-34,100,000	-7,900,000	-27,400,000	-330,500,000	-100,000	-42,500,000	-22,100,000	-36,700,000	-26,000,000		-61,300,000																																																													-4,631,000	-13,057,001	-7,999	-7,804,000	-5,937,000	-8,796,000	-12,425,000	-11,424,000	-9,571,000	-7,952,000	-9,242,000	-10,696,000	-9,854,000	-9,609,000	-7,081,000	-5,533,000
adjustments to reconcile net loss to net cash from operating activities:
depreciation and amortization	12,500,000	12,600,000	12,600,000	14,100,000	14,400,000	14,800,000	15,600,000	15,100,000	15,700,000	15,100,000	14,100,000	13,300,000	19,400,000	13,700,000	13,100,000	12,900,000	13,000,000	13,300,000	14,200,000	16,900,000	18,400,000	17,700,000	17,700,000	17,900,000	18,200,000	18,200,000	18,400,000	18,300,000	18,000,000	18,300,000	15,100,000	13,000,000	13,100,000	13,200,000	13,300,000	12,900,000	12,900,000	9,200,000	6,700,000	6,500,000	6,700,000	6,800,000	6,611,000	6,399,000	6,036,000	5,954,000	5,528,000	3,480,000	2,439,000	2,372,000	2,254,000	2,180,000	2,244,000	2,211,000	2,328,000	2,303,000	2,291,000	2,147,000	1,878,000	1,800,000	1,784,000	1,757,000	1,792,000	1,778,000	1,735,000	1,779,000	2,439,000	2,408,000	2,346,000	2,256,000	2,259,000	2,287,000	4,232,932	2,068	2,008,000	1,955,000	1,824,000	1,757,000	1,804,000	1,717,000	1,691,000	1,643,000	1,453,000	1,435,000	1,419,000	1,306,000	1,294,000
non-cash lease expense	1,000,000	1,100,000	1,000,000	2,800,000	2,800,000	2,800,000	2,300,000	2,100,000	2,300,000	2,700,000	2,800,000	2,900,000	2,900,000	3,100,000	2,900,000	2,600,000	3,100,000	3,000,000	3,000,000	3,300,000	3,500,000	3,300,000
stock-based compensation expense	6,500,000	2,800,000	12,200,000	10,700,000	9,500,000	10,900,000	12,400,000	14,500,000	12,000,000	10,400,000	11,600,000	11,200,000	7,500,000	8,200,000	9,400,000	10,400,000	10,100,000	8,400,000	10,000,000
unrecognized tax benefits		-1,000,000	0	-200,000	-31,300,000	1,300,000	300,000	300,000	600,000	600,000	500,000	400,000	1,900,000	-1,200,000	300,000	-400,000	200,000	-4,100,000	1,100,000	100,000	300,000	13,900,000	1,100,000	-100,000	300,000	400,000		-5,000,000	300,000	-2,600,000	-3,000,000	-5,500,000	1,500,000	6,700,000	300,000	300,000	200,000	400,000	0	-3,900,000	600,000	900,000	227,000	785,000	812,000	276,000	-3,583,000	323,000	962,000	1,638,000	240,000	340,000	0	130,000	0				200,000	648,000	-529,000	-467,000
impairment of goodwill and long-lived assets	5,400,000	2,700,000	0			43,000,000	800,000	11,600,000	1,200,000					6,200,000	0	0	10,700,000	0	0
other non-cash adjustments	1,200,000	1,800,000	1,300,000	-200,000	500,000	-500,000	200,000	900,000	900,000	-100,000	1,300,000
changes in assets and liabilities:
prepaid expenses and other current assets	-9,700,000	3,300,000	-3,400,000	2,500,000	-2,200,000	900,000	-2,500,000	3,100,000	-5,200,000	2,000,000			-4,000,000	1,200,000	-1,900,000	5,300,000	-3,000,000	100,000
trade accounts receivable	-8,700,000	2,600,000	19,000,000	-16,200,000	800,000	4,000,000	-8,200,000	-600,000	-3,900,000	1,200,000	-3,600,000	7,400,000	-17,500,000	2,500,000	6,100,000	-8,400,000	-10,500,000	2,800,000	700,000	-7,600,000	-4,700,000	-17,000,000	34,500,000	15,900,000	-3,100,000	16,700,000		-26,100,000	2,400,000	-3,300,000	3,100,000	-9,800,000	-16,000,000	-16,500,000	-1,100,000	-15,900,000	-18,500,000	-5,900,000	-10,500,000	-17,600,000	-7,500,000	-3,600,000	-2,161,000	-18,353,000	-12,365,000	-1,521,000	-7,065,000	-5,710,000	-8,218,000	-3,379,000	-11,351,000	-25,983,000	-20,591,000	-9,260,000	-16,758,000	-14,850,000	-4,517,000	1,181,000	-4,017,000	-10,161,000	-423,000	-388,000	-4,422,000	-3,836,000	-9,862,000	-3,540,000	-951,000	-10,187,000	1,540,000	-10,303,000	-4,112,000	-3,960,000	-12,983,474	-4,526	-7,452,000	-2,981,000	-2,458,000	-3,042,000	-795,000	-2,291,000	-564,000	-2,048,000
inventory	2,700,000	900,000	-2,900,000	-300,000	-900,000	-1,300,000	0	-3,100,000	-1,800,000	3,200,000	-2,700,000	-600,000	-1,700,000	1,500,000	-4,300,000	100,000	-200,000	3,200,000	-800,000	-3,200,000	2,400,000	2,600,000			-500,000	3,100,000	600,000	1,300,000	2,600,000	3,500,000	-1,000,000	4,800,000	800,000	3,300,000	5,300,000	3,900,000	2,600,000	-13,000,000	-14,400,000	3,900,000	5,100,000	-9,200,000	4,121,000	-8,667,000	4,602,000	-856,000	-5,399,000				2,129,000	3,331,000	135,000	972,000	-1,246,000	-69,000	-623,000	-1,488,000
prepaid taxes	10,000,000	1,800,000	500,000	0	2,100,000	600,000	1,300,000	0	-1,400,000	500,000	300,000			200,000	1,400,000	-500,000	-400,000	-18,100,000	18,200,000	-500,000	90,300,000	-107,900,000	25,400,000	-700,000	-1,700,000	2,100,000		100,000	500,000	-3,600,000		4,700,000	500,000	-8,900,000	0	4,000,000	600,000	-1,000,000	11,500,000	12,700,000	-14,500,000	-13,500,000	-9,000	5,602,000	13,096,000	-5,089,000	-521,000									5,936,000
other assets	-500,000	700,000	600,000	200,000	500,000		-900,000	500,000	200,000	800,000	4,900,000	-2,800,000	-2,300,000	-400,000	500,000	-700,000	-300,000	-400,000	-900,000	-1,500,000	-1,200,000	-1,200,000
accounts payable	5,400,000	-4,200,000	-800,000			-1,100,000	-3,600,000	3,300,000	6,100,000	-5,900,000	-8,500,000	3,100,000	7,600,000	-2,400,000	7,100,000	-5,000,000	-3,200,000	14,000,000	-12,900,000	7,800,000	300,000	-3,200,000		9,200,000	-2,000,000	-9,300,000	9,200,000	-7,800,000	8,100,000	-8,400,000	6,000,000	-5,000,000	2,600,000	400,000	-5,000,000	4,000,000	3,000,000	-5,000,000		-2,800,000	1,200,000	-5,300,000	3,300,000	-155,000	-8,895,000	2,650,000	4,143,000	-5,099,000	-1,149,000	613,000	5,894,000	-1,337,000	2,489,000	945,000	2,207,000	-954,000	-926,000	-1,576,000	3,966,000	-1,859,000	-192,000	-1,628,000	1,844,000	-2,377,000	1,755,000	-6,529,000	2,751,000	-1,345,000	-2,228,000	-9,885,000	12,875,000	-1,901,000	-1,851,230	-1,770	4,765,000	-4,199,000	3,547,000	-154,000	1,312,000	-4,216,000	4,988,000	-2,177,000	5,037,000	-1,919,000	-5,645,000
accrued liabilities	-7,400,000	-6,700,000	8,400,000	-16,800,000	-12,400,000	-27,500,000	6,600,000	-5,400,000	-14,700,000							-47,600,000	-35,300,000	-12,500,000	62,100,000	8,300,000	7,800,000	-9,800,000	17,000,000	-3,600,000	-10,100,000	-1,700,000	100,000	6,100,000	-300,000	-4,400,000	4,000,000	3,200,000	0	-5,800,000	1,300,000	4,400,000	4,500,000	-9,500,000	-2,400,000	3,400,000	5,200,000	-5,700,000	-1,876,000	3,709,000	526,000	-15,759,000	5,310,000	-3,743,000	-13,546,000	15,056,000	5,982,000	9,160,000	-13,804,000	10,224,000	5,068,000	4,105,000	3,518,000	-1,473,000	343,000	2,043,000	977,000	-2,439,000	2,408,000	1,883,000	-37,000	-4,647,000	-2,775,000	-15,801,000	1,643,000	-7,593,000	23,176,000	-526,000	5,086,938	2,062	4,003,000	714,000	-398,000	-3,662,000	3,993,000	2,416,000	-1,045,000	-1,508,000	-2,555,000	2,753,000	-899,000	583,000	205,000
net cash from operating activities	-15,700,000	10,600,000	21,100,000	-13,600,000	-16,300,000	6,600,000	700,000	2,600,000	-18,600,000	-54,700,000	-22,100,000	-900,000	-33,200,000	-7,700,000	-1,800,000	-50,300,000	-46,500,000	-9,900,000	-39,300,000	-4,400,000	71,800,000	-59,300,000	30,000,000	16,800,000	-1,900,000	15,800,000	31,500,000	6,600,000	37,800,000	7,800,000	47,900,000	11,500,000	33,000,000	23,500,000	36,600,000	41,100,000	31,400,000	-2,900,000	56,400,000	44,100,000	40,900,000	24,900,000	51,044,000	29,878,000	52,597,000	6,981,000	40,933,000	11,249,000	47,549,000	90,482,000	63,000,000	37,396,000	22,114,000	51,356,000	41,740,000	40,708,000	27,543,000	31,855,000	36,302,000	28,036,000	37,125,000	29,296,000	46,522,000	42,656,000	42,727,000	23,181,000	38,929,000	7,869,000	41,643,000	-4,399,000	111,840,000	4,444,000	-12,535,302	-12,698	254,000	-4,921,000	-6,883,000	-14,301,000	-3,288,000	-6,889,000	-6,900,000	-10,950,000	-3,996,000	-6,724,000	-13,675,000
cash flows from investing activities:
capital expenditures	-5,400,000	-4,700,000	-2,800,000	-2,800,000	-5,300,000	-3,600,000	-3,500,000	-5,200,000	-6,700,000	-10,000,000	-10,900,000	-18,800,000	-23,500,000	-14,600,000	-17,700,000	-6,700,000	-6,300,000	-3,400,000	-3,000,000	-4,500,000	-7,100,000	-1,500,000	0	-3,000,000	-3,400,000	-1,400,000	0	-3,100,000	-2,800,000	-1,300,000	-1,800,000	-2,900,000	-2,100,000	-1,600,000	-700,000	-1,500,000	-2,400,000	-1,500,000	-2,200,000	-700,000	-1,100,000	-1,000,000	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-1,393,000	-4,785,000	-2,480,000	-1,834,000	-2,594,000	-2,338,000	-914,000	-347,000	-1,086,000	-1,443,000
free cash flows	-21,100,000	5,900,000	18,300,000	-16,400,000	-21,600,000	3,000,000	-2,800,000	-2,600,000	-25,300,000	-64,700,000	-33,000,000	-19,700,000	-56,700,000	-22,300,000	-19,500,000	-57,000,000	-52,800,000	-13,300,000	-42,300,000	-8,900,000	64,700,000	-60,800,000	30,000,000	13,800,000	-5,300,000	14,400,000	31,500,000	3,500,000	35,000,000	6,500,000	46,100,000	8,600,000	30,900,000	21,900,000	35,900,000	39,600,000	29,000,000	-4,400,000	54,200,000	43,400,000	39,800,000	23,900,000	51,044,000	29,878,000	52,597,000	6,981,000	40,933,000	11,249,000	47,549,000	90,482,000	63,000,000	37,396,000	22,114,000	51,356,000	41,740,000	40,708,000	27,543,000	31,855,000	36,302,000	28,036,000	37,125,000	29,296,000	46,522,000	42,656,000	42,727,000	23,181,000	38,929,000	7,869,000	41,643,000	-4,399,000	111,840,000	4,444,000	-12,535,302	-12,698	254,000	-6,314,000	-11,668,000	-16,781,000	-5,122,000	-9,483,000	-9,238,000	-11,864,000	-4,343,000	-7,810,000	-15,118,000
capitalization of intangible assets	-1,100,000	-1,300,000	-3,400,000	-4,100,000	-3,000,000
net cash from investing activities	-6,500,000	-6,000,000	-6,200,000	-6,900,000	-8,300,000	-5,900,000	7,500,000	-6,400,000	-7,100,000	-12,000,000	-2,500,000	11,800,000	34,600,000	-35,600,000	11,400,000	-12,000,000	-41,300,000	-25,900,000	291,000,000	1,100,000	8,200,000	17,100,000	10,300,000	23,300,000	-7,200,000	-7,100,000		-3,800,000	-8,100,000	-279,000,000	8,900,000	-700,000	-4,600,000	-15,200,000	4,300,000	9,500,000	-2,100,000	-158,000,000	-43,800,000	-16,100,000	-40,500,000	9,000,000		24,885,000	-8,748,000	27,576,000	-19,861,000	-471,000	10,722,000	-8,057,000	-84,629,000	48,081,000			-8,174,000	-43,817,000	15,635,000	-2,532,000	-60,938,000	42,480,000	-52,605,000	16,673,000	11,971,000	-13,429,000	-76,522,000	1,312,000	-45,964,000	-17,851,000	-101,161,000	-41,366,000	-19,982,000	20,017,000	-31,309,985	-30,015	-58,411,000	6,922,000	1,202,000	3,546,000	-8,086,000	-9,090,000	-54,698,000	-955,000	8,318,000	513,000	265,000
cash flows from financing activities:
payment of tax withheld for common stock issued under stock-based compensation plans	-2,900,000	-1,200,000	-300,000	0	-5,800,000	-1,200,000	-3,000,000	-500,000	-8,700,000	-1,500,000	-2,200,000	-200,000	-4,900,000	-1,500,000	-3,800,000	-200,000	-5,100,000	-2,900,000	-8,000,000
proceeds from revolving credit facility		0	0	0	40,000,000	20,000,000	20,000,000	20,000,000	60,000,000	40,000,000	0
repayment of revolving credit facility		0	-60,000,000	0	-20,500,000	-19,500,000	-20,000,000	-20,000,000	-60,000,000									0	-106,400,000	-50,000,000	-70,000,000			0	0	-8,600,000		-10,000,000	-35,000,000	-40,000,000	-60,000,000	-27,000,000	-31,000,000	-25,000,000	-68,000,000
payment on finance leases	-100,000		-100,000	-100,000	-100,000	-100,000	-100,000	-100,000	-100,000	-100,000
net cash from financing activities	-3,000,000	-8,200,000	56,200,000	2,600,000	13,600,000	2,100,000	-3,100,000	2,400,000	-8,800,000	121,900,000	-2,500,000	38,400,000	-4,900,000	-2,100,000	-3,600,000	2,500,000	-4,800,000	-1,100,000	-74,500,000	-26,500,000	-48,500,000	-3,900,000		200,000	1,100,000	-12,300,000	-27,800,000	-9,400,000	-32,600,000	252,100,000	-41,300,000	-4,300,000	-26,100,000	-23,300,000	-63,300,000	-36,700,000	-4,000,000	175,800,000	-64,200,000	-42,200,000	48,400,000	-10,300,000	-40,188,000	-55,984,000	-52,274,000	-28,854,000	-42,049,000	3,421,000	-71,659,000	-101,511,000	13,379,000	-41,577,000	-15,237,000	-37,120,000	-52,029,000	-926,000	3,007,000	-19,297,000	9,868,000	-70,807,000	-40,156,000	-15,504,000	-67,802,000	12,491,000	3,030,000	3,193,000	-130,140,000	31,682,000	8,270,000	38,264,000	3,484,000	3,356,000	15,024,503	6,497	6,718,000	107,002,000	2,924,000	807,000	3,540,000	3,804,000	141,452,000	1,124,000	126,000	442,000	40,000
effect of foreign exchange rates on cash, cash equivalents, and restricted cash	-100,000	100,000	0	600,000	100,000	-700,000	1,200,000	-700,000	-800,000	700,000	-600,000	300,000	200,000
net decrease in cash, cash equivalents, and restricted cash	-25,300,000			-17,300,000	-10,900,000				-35,300,000				-3,300,000
cash, cash equivalents, and restricted cash at beginning of the period	151,300,000	0	0	0	111,900,000	0	0	0	140,900,000	0	0	0	66,400,000
cash, cash equivalents, and restricted cash at end of the period	126,000,000	-3,500,000	71,100,000	-17,300,000	101,000,000	2,100,000	8,600,000	-4,400,000	105,600,000	55,900,000	-27,700,000	49,600,000	63,100,000
deferred income taxes						200,000	-1,400,000	-2,200,000	600,000	-2,300,000	-1,000,000	-800,000	100,000	-8,800,000	-11,400,000	-4,700,000	-5,900,000	-4,300,000	-16,300,000	300,000	-11,800,000	48,400,000		-16,100,000	-1,700,000	-5,100,000	15,600,000	700,000	-400,000	2,700,000	1,400,000	1,000,000	-30,600,000	4,700,000	-700,000	-900,000	-300,000	3,200,000	-13,400,000	1,700,000	18,400,000	11,400,000	643,000	-2,934,000	-798,000	2,689,000	6,297,000	3,653,000	-1,238,000	-588,000	2,449,000	-879,000	3,675,000	2,224,000	-574,000	2,925,000	16,488,000	14,786,000	13,565,000	13,708,000	13,345,000	12,538,000
loss on termination of lease
gain on acquisition						0	0	0	-2,200,000
tenant improvement allowance received										0	0	3,100,000	13,200,000	9,400,000
proceeds from the sale of business, net cash sold						0
proceeds from maturities and sales of marketable investment securities						0	5,000,000	2,500,000	1,500,000	1,500,000	15,000,000	30,600,000	58,100,000	40,600,000	42,400,000	28,100,000	17,100,000	24,300,000	11,800,000	9,700,000	15,300,000	18,600,000	12,700,000	20,800,000	18,100,000	17,400,000	27,400,000	19,700,000	15,800,000	16,300,000	12,200,000	20,300,000	27,300,000	17,900,000	17,900,000	34,000,000	20,200,000	88,700,000	28,500,000	15,300,000	39,500,000	31,800,000	24,798,000	60,300,000	12,881,000	67,621,000		227,405,000	56,074,000	57,350,000		92,165,000	82,871,000	124,359,000		89,179,000	138,168,000	66,658,000		153,026,000
proceeds from common stock issued under stock-based compensation plans		600,000	0			2,900,000	0							2,400,000	900,000	2,700,000	300,000	1,800,000	39,900,000
proceeds from underwritten public offering, net of costs and discounts
proceeds from the issuance of secured long-term credit facility		0
fees associated with the issuance of secured long-term credit facility		-200,000
fees associated with issuance and refinancing of revolving credit facility
release of cash held in escrow
other financing activities
net increase in cash, cash equivalents, and restricted cash		-3,500,000				2,100,000	8,600,000			55,900,000	-27,700,000
gain on termination of lease							0	0	-3,100,000
proceeds from the sale of businesses, net of cash sold
change in cash and cash equivalents classified as held for sale
capitalization of internal-use software costs						-2,300,000	-2,800,000	-3,700,000	-1,900,000	-3,500,000
acquisitions, net of cash acquired																												0	1,100,000	-279,600,000					0	0	-3,100,000	-213,000,000					15,000
purchases of marketable investment securities														-4,400,000	-13,300,000	-33,400,000	-52,100,000	-46,800,000	-64,400,000					-15,800,000	-21,900,000	-23,100,000		-20,400,000	-22,200,000	-14,400,000	-1,500,000	-18,100,000	-29,800,000	-31,500,000	-12,900,000	-25,600,000	-16,800,000	-32,200,000	-33,100,000	-30,700,000	-78,900,000	-21,800,000	-25,631,000	-32,446,000	-16,754,000	-5,869,000	-56,313,000	-2,790,000	-42,519,000	-60,142,000	-162,003,000	-42,510,000	-112,361,000	-126,903,000	-97,213,000	-130,996,000	-118,576,000	-41,282,000	-86,190,000	-110,388,000	-181,056,000	-47,519,000	-146,517,000	-110,832,000	-165,041,000	-55,168,000	-91,899,000	-30,762,000	-122,849,000	-63,056,000	-33,421,000	-31,707,000	-126,492,174	-80,826	-107,143,000	-47,860,000	-14,553,000	-28,285,000	-49,765,000	-40,035,000	-69,360,000	-6,359,000	-4,750,000	-14,827,000	-14,161,000
payment of contingent consideration recognized at acquisition																		0	0	0	-3,300,000	-100,000		0	-600,000	-3,300,000
bad debt expense							-100,000																								9,100,000	7,200,000	8,000,000	8,000,000	10,000,000	9,200,000	10,900,000	7,200,000	9,800,000	9,000,000	8,500,000	6,000,000	7,980,000	9,561,000	6,858,000	7,101,000	8,267,000	9,175,000	10,299,000	11,494,000	10,191,000	8,374,000	7,534,000	7,195,000	7,251,000	6,902,000	6,331,000	4,258,000	3,845,000	3,788,000	4,189,000	4,360,000	4,739,000	4,487,000	4,829,000	4,421,000	3,807,000	4,146,000	3,962,000	4,032,000	3,153,000	2,724,000	5,620,859	2,141	1,810,000	1,526,000	1,614,000	700,000	489,000	756,000	332,000	537,000	548,000	210,000	148,000	100,000	120,000
net realized losses on marketable investment securities										0	100,000	900,000	500,000
deferred revenues									100,000		100,000	0	100,000		0	-400,000	-4,500,000
net loss attributable to myriad genetics, inc. stockholders														-42,300,000	-35,100,000	-14,100,000	-20,500,000		24,600,000	-4,700,000	-39,500,000	-15,200,000
loss on inventory																		0	-100,000
gain on sale of businesses and assets																		0
deferred revenue																				-7,600,000	-1,600,000	-600,000	28,900,000	200,000				-100,000	-100,000	-200,000	0	-800,000	100,000	600,000	-100,000	500,000	1,500,000	-1,000,000				-100,000	158,000	-492,000	481,000	253,000	-1,078,000	-1,986,000	3,057,000	-1,148,000	-988,000	310,000	-554,000	1,221,000	685,000	-1,059,000	1,367,000	-245,000									-25,000	-172,000	222,000	-2,025,000	-25,000	1,725,000	-49,626	-374	-24,000	-27,000	376,000	-59,000	-76,000	-190,000	-2,707,000	2,747,000	-532,000	-154,000	-583,000
proceeds from sale of business and assets
accrued expenses and other liabilities											21,100,000	71,800,000	-6,500,000
fees associated with issuance of revolving credit facility											-200,000
fees associated with refinancing of revolving credit facility														0				0	0	0	-1,200,000
net income													-54,700,000																							4,200,000	5,900,000	-1,200,000	35,700,000	32,600,000	30,400,000	26,600,000	18,712,000	21,475,000	24,031,000	15,982,000	33,632,000	36,768,000	50,360,000	55,465,000	44,074,000	37,893,000	35,036,000	30,136,000	29,142,000	29,615,000	28,295,000	25,099,000	26,040,000	27,941,000	24,191,000	22,538,000	53,250,000	33,251,000	35,360,000	30,442,000	23,640,000	25,318,000	21,203,000	14,454,000
adjustments to reconcile net income to net cash from operating activities:
non-cash interest expense													300,000	600,000	700,000	200,000	200,000	200,000	500,000	300,000	500,000	200,000	200,000	100,000	100,000	100,000	100,000	1,500,000	100,000	-1,300,000	100,000	0	0	100,000	0	100,000	200,000	100,000
non-cash impact of foreign currency transactions
gain on sale of assets
proceeds from sale of assets
effect of foreign exchange rates on cash and cash equivalents															-500,000	-200,000	-600,000	100,000	-400,000	-700,000	400,000	700,000	1,400,000	-2,000,000	800,000	300,000	100,000	900,000	200,000	1,500,000	-2,000,000	2,200,000	-1,500,000	500,000	1,000,000	1,900,000	-4,200,000	3,500,000	-400,000	0	-1,500,000	-300,000	869,000	-3,279,000	-1,669,000	-721,000									-37,000	39,000	-13,000	-31,000
net increase in cash and cash equivalents															5,500,000	-60,000,000	-93,200,000	-36,800,000	176,800,000	-30,500,000	31,900,000		42,700,000								13,500,000	8,700,000	800,000	-14,500,000	-21,400,000	15,800,000	21,100,000	18,400,000	-52,000,000	-14,200,000	47,300,000	23,300,000				4,982,000	-20,977,000			-19,086,000	-8,250,000	43,900,000	-27,160,000	9,231,000	-18,500,000	-3,996,000	46,172,000	9,995,000	-14,697,000			30,465,000	-9,309,000			27,686,000									-51,439,000	109,003,000			-7,834,000	-12,175,000						-18,818,000	-16,606,000
cash and cash equivalents at beginning of the period															0	0	258,400,000	0	0	0	117,000,000	163,700,000		0	0	93,200,000		0	0	110,900,000		0	0	102,400,000		0	0	68,500,000		0	0	64,100,000
cash and cash equivalents at end of the period															5,500,000	-60,000,000	165,200,000	-36,800,000	176,800,000	-30,500,000	148,900,000	118,300,000		39,800,000	-8,700,000	89,900,000		-5,700,000	-2,700,000	93,300,000		8,700,000	800,000	87,900,000		15,800,000	21,100,000	86,900,000		-14,200,000	47,300,000	87,400,000
net income attributable to myriad genetics, inc. stockholders																								-115,200,000	-8,300,000	-20,600,000	-4,200,000	6,900,000	2,600,000	-700,000	6,500,000	11,400,000
payment of contingent consideration																															-1,900,000
repurchase and retirement of common stock																												0							0	0	-10,300,000	-21,300,000	-54,700,000	-45,000,000	-24,900,000	-38,000,000	-44,754,000	-61,994,000	-58,323,000	-45,629,000	-65,689,000	-41,890,000	-77,808,000	-102,316,000	-21,563,000	-44,822,000	-33,684,000	-46,199,000	-60,996,000	-12,005,000	-18,285,000	-37,181,000	-21,883,000	-88,071,000	-61,930,000	-28,606,000
change in fair value of contingent consideration																			400,000	400,000	900,000	-1,100,000	0	2,100,000	0	700,000		0	-1,000,000	-400,000	400,000	-1,100,000	13,000,000	-73,200,000	-2,800,000	5,200,000
proceeds from sale of businesses and assets
gain on deconsolidation of subsidiary
prepaid expenses																				-2,600,000	-2,100,000	1,200,000	-1,300,000	3,700,000	-2,800,000	2,600,000		1,200,000	-1,000,000	1,800,000	600,000	-200,000	-300,000	3,200,000	-3,100,000	2,600,000	500,000	7,800,000	1,500,000	-11,500,000	-4,200,000	7,000,000	-2,555,000	-2,172,000	1,725,000	-2,498,000	-4,649,000	-2,644,000	701,000	1,106,000	579,000	784,000	197,000	-803,000	423,000	947,000	202,000	-368,000	-2,231,000	1,355,000	1,410,000	-946,000	-1,145,000	3,022,000	1,980,000	-3,918,000	-1,422,000	-62,000	353,000	41,000	3,889,000	3,724,000	-4,778,211	-5,789	289,000	1,144,000	-2,151,000	545,000	771,000	3,640,000	-2,098,000	-1,308,000	171,000	-893,000	101,000
other receivables																				700,000	-400,000	900,000	-300,000	1,200,000	-200,000	-100,000		1,500,000	-1,600,000	-300,000	-3,000,000	2,700,000	1,100,000	300,000	-800,000	-800,000	-600,000	-1,800,000	100,000	4,300,000	-5,500,000	200,000	1,545,000	2,516,000	5,913,000	-7,474,000	-1,283,000	-415,000	-1,730,000	1,558,000	-1,179,000	-1,199,000	982,000	690,000	-1,160,000	-536,000	-537,000	-79,000	749,000	-948,000	51,000	-54,000		-807,000	636,000	-420,000	3,517,000	-3,459,000	6,432,000	-2,409,000	-2,751,000	582,000	-1,250,789	-1,211	782,000	790,000	-2,174,000	651,000	-323,000	-60,000	-36,000	167,000	4,167,000	3,129,000	1,013,000
proceeds from sale of subsidiary																							0
gain on disposition of assets																					-300,000					-100,000							200,000	-100,000		0	0	-200,000			0	-400,000																-4,000
share-based compensation expense																					9,000,000	8,400,000	1,900,000	7,500,000	7,000,000	8,800,000	8,800,000	9,500,000	7,500,000	7,700,000	7,100,000	6,700,000	6,900,000	6,400,000	7,200,000	7,500,000	7,400,000	7,800,000	7,700,000	7,600,000	7,600,000	8,700,000	14,128,000	12,544,000	12,148,000	6,880,000	6,565,000	6,711,000	6,857,000	6,935,000	6,177,000	6,731,000	7,104,000	6,600,000	6,416,000	6,588,000	6,607,000	6,664,000	6,373,000	6,224,000	6,118,000	6,373,000	5,803,000	4,977,000	6,618,000	5,378,000	7,494,000	6,971,000	6,170,000	5,047,000	4,835,000	4,355,000	6,222,574	2,426	2,525,000	2,126,000	1,733,000	1,361,000	973,000	887,000	490,000	239,000
impairment of goodwill and intangible assets																							0
cash flows from investing activities
proceeds from common stock issued under share-based compensation plans																					26,500,000
payment of tax withheld for common stock issued under share-based compensation plans																					-500,000
loss on disposition of assets																						100,000						0	100,000	-1,000,000									-500,000				421,000	95,000	-85,000	69,000	803,000	12,000	0	40,000	4,000												129,000	302,000	-223,000	288,000	454,000				0	65,000	271,726	274	-648,000	-32,000	0	27,000	-12,000	23,000			5,000	0	10,000
payment for tax withholding for common stock issued under share-based compensation plans																						-3,800,000
net decrease in cash and cash equivalents																						-45,400,000			-8,700,000	-3,300,000		-5,700,000	-2,700,000	-17,600,000														-4,500,000																								21,700,000	-51,248,000	-7,501,000		27,817,000	-28,820,784	-36,216				-9,948,000				-10,781,000		-5,769,000	-13,370,000
net proceeds from common stock issued under share-based compensation plans																							2,000,000	200,000	1,700,000	-400,000	2,200,000	2,000,000	2,400,000	2,100,000	18,700,000	11,900,000							8,400,000	1,000,000	62,100,000	22,800,000	4,365,000	5,440,000	5,096,000	15,099,000	17,606,000	40,794,000	5,571,000	791,000	32,319,000	1,603,000	15,287,000	8,616,000		10,371,000			17,102,000	775,000	6,439,000	744,000	3,591,000	12,491,000	3,030,000	3,193,000	5,993,000			38,264,000	2,284,000	3,356,000	15,024,503	6,497	6,720,000	1,720,000	2,924,000	807,000	3,541,000	3,811,000
proceeds from non-controlling interest																															0	200,000
cash and cash equivalents at beginning of year
cash and cash equivalents at end of year
net proceeds from revolving credit facility																												0	50,000,000	290,000,000	0				0	0
impairment of goodwill classified as held for sale
impairment of cost basis investment																																			0	-100,000
loss on extinguishment of debt																																			0	0
sale of cost basis investment																																			0
net proceeds from term loan																																			0	0
repayment of term loan																																			0	0
fees associated with restructure of debt
payment of contingent consideration recorded in purchase accounting
fees paid for extinguishment of debt																																			0	0
net income (loss) attributable to myriad genetics, inc. stockholders																																		81,100,000
net proceeds from (payments for) common stock issued under share-based compensation plans																																		1,700,000
net proceeds from issuance of debt																																						199,000,000
excess tax benefit from share-based compensation																																								-1,800,000	-11,200,000	-4,900,000	-201,000	-570,000	-953,000	-1,676,000	-6,034,000	-4,517,000	-578,000	-14,000	-2,623,000	-1,642,000	-3,160,000	-463,000	-1,996,000	-708,000	-14,449,000	-17,040,000	-14,649,000	-16,489,000
net proceeds for common stock issued under share-based compensation plans																																				300,000	2,900,000	-1,900,000
accreted interest on note receivable																																															0	-2,004,000	-667,000	-666,000	-667,000	-667,000	-666,000	-667,000	-667,000	-666,000
gain on remeasurement of foreign currency
restricted cash																																													1,071,000	-22,674,000
impairment of intangible assets
gain on sale of marketable investment securities
equity investment
net cash from (used) in investing activities
changes in operating assets and liabilities:
capital expenditures for equipment and leasehold improvements																																												-4,457,000	-5,946,000	-11,502,000	-4,618,000	-1,555,000	-2,833,000	-5,265,000	-2,791,000	-1,574,000	-4,547,000	-2,461,000	-2,192,000	-2,000,000	-3,107,000	-2,109,000	-610,000	-158,000	-1,065,000	-1,959,000	-827,000	-1,148,000	-4,343,000	-1,577,000	-2,175,000	-1,841,000	-2,575,000	-934,000	-4,006,000	-1,513,000	-8,152,718	-3,282
cash and cash equivalents at beginning of period																																												0	0	64,821,000		0	0	104,073,000		0	0	86,352,000		0	0	52,681,000		0	0	92,840,000		0	0	63,510,000		0	0	237,734,000		0	143,288,568	143,432		0	0	98,573,000		0	0	49,509,000	0	0	61,603,000		0
cash and cash equivalents at end of period																																												-4,500,000	-10,094,000	69,803,000		14,199,000	-13,388,000	84,987,000		43,900,000	-27,160,000	95,583,000		-3,996,000	46,172,000	62,676,000		-291,000	-55,636,000	123,305,000		41,718,000	-30,765,000	91,196,000		21,700,000	-51,248,000	230,233,000		27,817,000	114,467,784	107,216		109,003,000	-2,757,000	88,625,000		-12,175,000	79,854,000	38,728,000	4,448,000	-5,769,000	48,233,000		-16,606,000
non-cash expense related to in-process research and development technology																																																							0	0			500,000	0
acquisition of crescendo biosciences, inc. (see note 12), net of cash acquired
acquisition of rules-based medicine, inc., net of cash acquired
purchase of in-process research and development technology																																																							0	0			-500,000	0
purchase of other assets																																																							0	0			0	0			0	0				0	-100,000	-2,000,000
purchase of an acquisition option
issuance of note receivable																																																							0	0	0	-17,000,000
proceeds from maturities and sales marketable investment securities
supplemental cash flow information:
cash paid during the year for income taxes
non-cash investing and financing activities:
fair value adjustment on marketable investment securities recorded to stockholders’ equity
impairment of intangible asset																																																				0
acquisition of crescendo biosciences, inc. (see note 9), net of cash acquired
acquisition of rules-based medicine, inc. (see note 12), net of cash acquired
acquisition of myriad rbm, inc.
crescendo purchase option																																																								0	0	-8,000,000
loss of disposition on assets																																																					3,000	1,000
net cash from provided by investing activities																																																						-5,005,000
acquisition of rules-based medicine, inc. (see note 13), net of cash acquired
proceeds from sale of intellectual property
net proceeds from common stock issued undershare-based compensation plans																																																										844,000
loss on sale of marketable investment securities																																																								-537,000	-22,000	-7,000	-38,000	-14,000	39,000	10,000	-236,000	-24,000
acquisition of rules-based medicine, inc.																																																									0	-799,000
acquisition of rules-based medicine, inc. (see note 14), net of cash acquired
cash and cash equivalents contributed to myriad pharmaceuticals, inc.
transfer of assets, net of liabilities to myriad pharmaceuticals, inc.
sale of intellectual property
net (decrease) in cash and cash equivalents
excess tax benefit from stock-based compensation																																																														-12,358,000
proceeds from sales and maturities of marketable investment securities																																																														66,151,000																34,311,000	43,513,000	33,539,000	17,100,000	6,318,000	13,415,000	16,526,000	15,869,000		7,396,000
loss on cost-basis investment
proceeds from maturities marketable investment securities
proceeds from sales marketable investment securities
cash and cash equivilants contributed to myriad pharmaceuticals, inc.
proceeds from sales of and maturities of marketable investment securities																																																																98,251,000
loss on marketable investment securities																																																																		-73,000
proceeds from maturities of marketable investment securities																																																																		58,057,000	48,110,000	14,752,000	24,363,000	24,624,000	17,694,000	53,237,000	103,434,907	54,093	51,474,000	56,175,000
other-than-temporary impairment on marketable investment securities																																																																			0	0
decrease in other assets
net proceeds from public offering of common stock																																																																											-2,000				-1,000	-7,000
net proceeds from warrants
supplemental disclosures of noncash information
fair value adjustment on marketable investment securities credited to stockholders’ equity
transfer of assets, net of liabilities to myriad pharmaceutical, inc.
other than temporary impairment on marketable investment securities																																																																						1,986,000
increase in other assets																																																																																			0
supplemental disclosures of noncash investing and financing activities:
fair value adjustment on marketable investment securities charged to stockholders’ equity
sales (purchases) of other assets																																																																								0				0
impairment charge on investments in other companies
acceleration of option vesting
changes in operating assets:
related party receivables																																																																																			576,000	-400,000	-26,000
purchases of other assets																																																																																0
net proceeds from issuance of common stock																																																																																		1,124,000	126,000	442,000	40,000	565,000	14,000
gain on sale of investment securities
trade receivables																																																																																			-2,170,000	-1,031,000	396,000
related party payable
maturities of investment securities held-to-maturity
purchases of investment securities available-for-sale
maturities/sales of investment securities available-for-sale
adjustments to reconcile net loss to net cash used in operating activities:
loss on disposition/impairment of assets
investments in other companies
proceeds from sale of investments in other companies
purchases of investment securities held-to-maturity
net cash provided by investing activities
net cash provided by financing activities

Myriad Genetics, Inc(NASDAQ:MYGN)

Myriad Genetics, Inc
(NASDAQ:MYGN)